Hereditary Spherocytosis - UpToDate

12/26/23, 11:14 PM Hereditary spherocytosis - UpToDate
Official reprint from UpToDate®

www.uptodate.com © 2023 UpToDate, Inc. and/or its affiliates. All Rights Reserved.
Hereditary spherocytosis
AUTHOR: Theodosia Kalfa, MD, PhD
SECTION EDITOR: Robert T Means, Jr, MD, MACP
DEPUTY EDITOR: Jennifer S Tirnauer, MD
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Nov 2023.

This topic last updated: Oct 25, 2023.
INTRODUCTION
Although relatively rare, hereditary spherocytosis (HS) is the most common cause of hemolytic
anemia due to a red cell membrane defect. It is a result of heterogeneous alterations in one of
five genes that encode red blood cell (RBC) membrane proteins involved in vertical associations
that link the membrane cytoskeleton to the lipid bilayer.
The genetics, pathophysiology, clinical features, diagnosis, and treatment of HS will be reviewed
here. Other inherited RBC membrane disorders, including hereditary elliptocytosis (HE),
hereditary pyropoikilocytosis (HPP), and hereditary stomatocytosis (HSt), are discussed
separately, as are general approaches to the evaluation of hemolytic anemia.
● HE and HPP – (See "Hereditary elliptocytosis and related disorders".)

● HSt – (See "Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)".)
● Hemolytic anemia, child – (See "Overview of hemolytic anemias in children".)
● Hemolytic anemia, adult – (See "Diagnosis of hemolytic anemia in adults".)
PATHOPHYSIOLOGY bất thường gen mã hóa màng HC và bộ xương tế bào, cụ thể: thiếu lớp liên kết dọc giữa
khung tế bào và lớp lipid kép của màng HC
HS is a heterogeneous group of disorders caused by variants in certain genes that encode
proteins of the red blood cell (RBC) membrane and cytoskeleton ( figure 1); specifically, HS is
caused because of inadequate vertical linkages between the cytoskeleton and the lipid bilayer
of the RBC membrane ( figure 2) [1,2]. The loss of vertical linkages leads to loss of RBC
https://www.uptodate.com/contents/hereditary-spherocytosis/print?search=spherocytosis&source=search_result&selectedTitle=1~58&usage_type=d… 1/76
membrane and a spherocytic (rather than biconcave disc) shape of HS RBCs, with decreased
surface-to-volume ratio and decreased deformability that is essential to the normal RBC
lifespan. (See "Red blood cell membrane: Structure and dynamics".)
Genetics
Overview of the proteins and genes involved — HS is caused by quantitative deficiency of

alpha- or beta-spectrin, ankyrin, protein 4.2, or band 3, encoded by the genes SPTA1, SPTB, ANK1,
EPB42, and SLC4A1, respectively [2-4]. The studies that have evaluated specific gene variants
have generally found that pathogenic variants in these genes tend to be distributed throughout
the gene, producing an abundance of variants that are private to individual kindreds rather
than localized to specific "hotspots"; this is illustrated in the figure ( figure 1) [5-7].
● Spectrin – Erythrocyte spectrin is composed of alpha-beta heterodimers; the proteins are

encoded by the SPTA1 and SPTB genes, respectively.
● Ankyrin – Erythrocyte ankyrin is encoded by the ANK1 gene. (See 'Ankyrin deficiency due
to ANK1 pathogenic variants' below.)
● Band 3 (the anion exchanger AE1) – This anion channel is encoded by the solute carrier
family 4 anion exchanger 1 (SLC4A1) gene. (See 'Band 3 deficiency due to SLC4A1 variants'
below.)
● Protein 4.2 (also called band 4.2) – Protein 4.2 is encoded by the EPB42 gene. In the past,
protein 4.2 was briefly referred to as pallidin, which is now recognized as a different
protein [8,9]. (See 'Band 4.2 deficiency due to EPB42 variants' below.)
● Information from mouse models – The roles of these variants in causing spherocytosis
has been studied in several genetically engineered animal models (transgenic mice) and in
naturally occurring variants in mice and cattle [10-14]. In the neonatal anemia (Nan)
mouse, the variant p.E339D in KLF1, the gene that encodes the erythroid transcription
factor Krüppel-like factor 1, results in deficiencies of multiple membrane proteins (alpha
spectrin, beta spectrin, ankyrin, band 3, and band 4.1R) and clinical features of HS
(spherocytic anemia) [15,16]. The substitution p.E325K in the KLF1 gene, corresponding to
the Nan mutation, causes congenital dyserythropoietic anemia (CDA) type IV, with
disordered erythropoiesis due to widespread transcriptomic changes affecting many more
genes than the ones encoding membrane proteins [17,18].
● Methods of analysis – Quantitative evaluation of the RBC membrane proteins with

electrophoresis and immunoblotting, after isolating RBC ghosts with osmotic lysis of RBCs
and washing out the hemoglobin and other cytoplasmic proteins, have been used for
decades to research and evaluate the protein pathology causing spherocytosis. The
discovery of the structural components of the red blood cell cytoskeleton coincided and
developed in parallel with the technique of sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) as a tool for protein chemistry in the 1970s [1]. Decrease in a
specific protein would be followed up later with sequencing of the corresponding gene,
deepening the understanding of erythroid and protein biology along with meticulous work
of many research teams around the world.
The introduction of next generation DNA sequencing to clinical diagnostics in

approximately 2010 has immensely facilitated diagnosis of RBC and erythropoiesis
disorders. Genotype-phenotype correlations associated with HS genes are summarized in
the sections below. Additional information about the assembly of these proteins is
presented separately. (See "Red blood cell membrane: Structure and dynamics", section on
'Composition of the membrane/cytoskeleton'.)
● Concomitant loss of other membrane proteins – Due to the tight interactions of the RBC
cytoskeleton proteins, protein chemistry frequently demonstrates a combination of
protein changes. As examples:
• Alpha spectrin deficiency due to SPTA1 pathogenic variants can be associated with
concomitant decreases in beta spectrin.
• Ankyrin deficiency due to ANK1 variants is accompanied by secondary spectrin

deficiency due to reduced incorporation of spectrin into the membrane since ankyrin is
the principal binding site for membrane spectrin [13].
• SLC4A1 variants can also cause secondary band 4.2 deficiency.
• Band 3 loss is a typical finding in all types of spherocytosis regardless of the genetic
cause since band 3 is lost along lipid membrane during the development of
spherocytes [5].
● Related, non-HS disorders – Variants affecting protein 4.1R, encoded by the EPB41 gene,
have not been reported in HS. Protein 4.1R is an integral component of the junctional
complex, participating in the horizontal associations of the RBC cytoskeleton; pathogenic
variants of this gene cause hereditary elliptocytosis (HE). (See "Hereditary elliptocytosis
and related disorders".)
Similarly, pathogenic variants in SPTA1 (encodes alpha spectrin) and SPTB (encodes beta
spectrin) that cause qualitative rather than quantitative spectrin abnormalities cause HE
rather than HS. Rare pathogenic variants in SPTA1 and SPTB that cause both in spectrin
deficiency (a feature of HS) as well as abnormal spectrin tetramer formation (a feature of
HE) cause hereditary spherocytic elliptocytosis or pyropoikilocytosis [19-21]. (See
"Hereditary elliptocytosis and related disorders".)
Variants affecting the Rh-associated glycoprotein, encoded by the RHAG gene, cause
overhydrated hereditary stomatocytosis, while variants in PIEZO1 and KCNN4 cause
dehydrated hereditary stomatocytosis or xerocytosis. (See "Hereditary stomatocytosis
(HSt) and hereditary xerocytosis (HX)".)
Inheritance patterns — The following inheritance patterns are seen, in some cases related to
the specific genes involved:
● HS may be inherited in an autosomal dominant fashion, caused by heterozygous

pathogenic variants in ANK1, SLC4A1, or SPTB, seen in approximately 65 to 70 percent of
cases [4,6].
● An additional 5 to 15 percent of cases are autosomal recessive, caused by biallelic variants

in SPTA1, EPB42, or ANK1 [2,22-25].
● The remaining 15 to 20 percent of cases appear to be due to de novo pathogenic variants

[26-31]. Most commonly these occur in the ANK1 gene, likely due to its high G/C content,
which predisposes to slipped strand mis-pairing during DNA replication [32].
● A few cases of autosomal recessive HS associated with biallelic ANK1 variants have been
described, in which a nonsense variant occurs in trans to a promoter or intronic variant
affecting levels of expression, or to a missense variant decreasing but not obliterating the
incorporation of ankyrin into the cytoskeleton, leading to a severe, transfusion-dependent
disease that remains amenable to treatment with splenectomy [6].
● Very rare cases of autosomal recessive HS due to biallelic SLC4A1 variants have been
reported in infants, some requiring in-utero transfusions or born prematurely with life-
threatening hydrops fetalis. These infants have severe transfusion-dependent HS, not
improving with splenectomy [33,34]. Findings are similar to the most severe form of SPTA1-
associated HS due to complete alpha-spectrin deficiency [35]. Biallelic truly null SPTB
variants have not been described, indicating that complete beta-spectrin deficiency may
be incompatible with life [2].
Ankyrin deficiency due to ANK1 pathogenic variants — Ankyrin is the major protein
responsible for the mechanical coupling between the lipid bilayer of the RBC membrane and
the underlying spectrin-based cytoskeleton. Ankyrin, along with protein 4.2, anchors the
transmembrane protein complexes, composed of band 3 and the Rh-associated glycoprotein
(RhAG), to the spectrin tetramers.
● Over 250 ANK1 pathogenic variants have been described and included in the Human Gene
Mutation Database (HGMD) [36,37]. These include missense/nonsense variants, splicing
and regulatory substitutions, small and large deletions, insertions, and duplications. Many
of these variants are "private" (found in only a single kindred) [38,39].
● ANK1-associated HS is typically an autosomal dominant disease, caused by a monoallelic

pathogenic variant, decreasing the expression or incorporation to the cytoskeleton of only
up to 50 percent of the ankyrin normally produced. A few cases have been described with
biallelic variants, causing recessive, more severe spherocytosis; in those cases (as also
discussed above) a null variant is present in trans to a promoter or intronic variant, or a
missense variant decreasing but not obliterating expression from that second allele or the
amount of protein incorporated in the cytoskeleton. Such combinations lead to a more
severe, frequently transfusion-dependent disease, but anemia is still amenable to
treatment with splenectomy [6,40].
Patients with a deletion of the short arm of chromosome 8, which contains the ANK1 gene,
have been described; these individuals have HS, intellectual disability, and other
congenital anomalies [41].
Band 3 deficiency due to SLC4A1 variants — Band 3 has two major functions. It provides
cohesion between the RBC plasma membrane and the underlying cytoskeletal proteins,
preventing membrane surface loss, and it exchanges bicarbonate for chloride ions, maintaining
RBC water content and preventing cellular dehydration.
HS due to SLC4A1 pathogenic variants is typically an autosomal dominant disease presenting as

mild hemolytic anemia or even compensated hemolysis. Documented pathogenic variants
include missense and nonsense mutations, splicing and regulatory substitutions, small
deletions, insertions, or indels, as well as gross deletions and insertions [5,7,37,42-48].
Hemolysis may be aggravated by compound heterozygosity for a pathogenic variant in SLC4A1
in trans to a low-expression band 3 allele [49,50].
Very rare cases of autosomal recessive HS due to biallelic SLC4A1 null variants have been
reported in infants requiring in-utero transfusions or born prematurely with life-threatening
hydrops fetalis. These infants have severe transfusion-dependent HS, not improving with
splenectomy, in addition to severe distal renal tubular acidosis (RTA) [33,34]. (See "Etiology and
diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis".)
Variants in SLC4A1 affecting band 3 can cause other disorders besides HS:
● SAO – A heterozygous deletion of the codons 400 to 408 is the pathogenic variant causing
Southeast Asian ovalocytosis (SAO) ( picture 1). The molecular change is a deletion of
nine amino acids spanning between the cytoplasmic and membrane domain of the band 3
protein causing inactivation of its anion exchanger function, along with a tighter
attachment to ankyrin and reduced lateral mobility of the channel, likely underlying the
marked rigidity of SAO RBCs [51,52]. Details are discussed separately. (See "Southeast
Asian ovalocytosis (SAO)".)
● Distal RTA – Individuals with certain SLC4A1 pathogenic variants causing loss of the anion
exchanger function of band 3 can present with an autosomal dominant or autosomal
recessive form of distal RTA. Some of these individuals may have HS [43]; however, most of
them do not, since glycophorin A (GPA) present in RBCs but not kidney epithelial cells
chaperones the distal RTA-causing band 3 molecules to the RBC membrane efficiently
[33,43,53-58]. Patients with SAO and distal RTA have been shown to be compound
heterozygous for the SAO causing deletion (∆400-408) and a distal RTA-causing variant
[59]. (See "Etiology and clinical manifestations of renal tubular acidosis in infants and
children", section on 'Genetic causes' and "Etiology and diagnosis of distal (type 1) and
proximal (type 2) renal tubular acidosis", section on 'Distal (type 1) RTA'.)
● HS due to protein 4.2 deficiency – The SLC4A1 gene encodes the antigens of the Diego
blood group system [60]. Polymorphisms in the gene cause variability of the Diego
antigens, which are important for transfusion medicine and neonatal alloimmune
hemolytic anemia; however, they are not causing HS or any other RBC pathologies. A
notable exception is the common polymorphism c.118G>A (pGlu40Lys), named band 3
Montefiore, which in the homozygous state decreases the incorporation of protein 4.2 into
the RBC cytoskeleton by approximately 88 percent, causing HS due to protein 4.2
deficiency [61].
● Cryohydrocytosis – Certain heterozygous SLC4A1 single amino-acid substitutions in the

transmembrane domain of RBC band 3 convert its function from an anion exchanger (AE1)
into an unregulated cation channel, leaking intracellular K+ with a temperature-
dependent, passive diffusion process [62]. Such SLC4A1 pathogenic variants cause
cryohydrocytosis, a form of hereditary stomatocytosis, where the K+ leak decreases at
room temperature (23°C) and increases to a maximum when the temperature approaches
5°C [63]. This K+ leak via the altered AE1 channel disturbs the osmotic balance and surface-
to-volume ratio of the RBCs, leading to chronic hemolysis [64,65].
● Stomatocytosis and dyserythropoiesis – A de novo band 3 variant (p.G796R-band3

CEINGE) was shown to be associated with stomatocytosis and a dyserythropoietic anemia
phenotype on bone marrow studies [66].
SLC4A1 pathogenic variants appear to cause approximately 5 percent of HS cases. (See

'Overview of the proteins and genes involved' above.)
However, this may be an underestimate since SLC4A1-associated HS is typically mild and

infrequently investigated with clinical sequencing. As mentioned above, band 3 deficiency is a
typical phenotypic finding in all types of spherocytosis regardless of the genetic cause since
band 3 is lost from the RBC lipid membrane in the process of spherocyte development. (See
Beta spectrin or alpha-spectrin deficiency due to SPTB or SPTA1 pathogenic

variants — beta-spectrin (encoded by SPTB) and alpha-spectrin (encoded by SPTA1) associate in
a rod-like heterodimer; two of these heterodimers associate head to head in tetramers that
make the sides of each triangular unit in the hexagonal structure of the RBC cytoskeleton.
While spectrin heterotetramers are the main components of the horizontal cytoskeleton, they
are also critical for the vertical interactions with the lipid membrane via their binding to
ankyrin/band 3 complexes ( figure 2). Qualitatively abnormal spectrin causes hereditary
elliptocytosis (HE); conversely, quantitative decreases in the amount of spectrin produced or
incorporated to the cytoskeleton due to pathogenic variants in the corresponding genes causes
HS [2,67]. Abnormalities in both the quality and the quantity of beta-spectrin or alpha-spectrin
incorporated into the RBC cytoskeleton cause a mixed phenotype of spherocytic
elliptocytosis/pyropoikilocytosis [20,21]. (See "Hereditary elliptocytosis and related disorders",
section on 'Hereditary spherocytic elliptocytosis (HSE)'.)
HS due to SPTB pathogenic variants is an autosomal dominant disease that presents as mild to
moderate hemolytic anemia. Recessive disease due to truly null biallelic SPTB variants has not
been described, indicating that complete deficiency of beta-spectrin is likely to be lethal early in
embryonic life. A multitude of pathogenic variants has been described, most of them nonsense
mutations, with a few missense mutations, several splicing variants, small deletions, insertions,
or indels, as well as gross deletions, insertions, and complex rearrangements [36,48,68-76].
HS due to alpha-spectrin deficiency is an autosomal recessive disease. Each SPTA1 allele

produces alpha-spectrin well in excess; therefore, biallelic pathogenic variants are required in
SPTA1 to decrease production of the protein enough to cause disease [35,77-81]. The typical
genotype for this type of HS is a null SPTA1 variant, such as a nonsense, frameshift, or splicing
variant causing nonsense-mediated decay, or whole gene deletion, in trans to the deep intronic
variant c.4339-99C>T, also known as alpha-LEPRA (Low Expression PRAgue), which severely
decreases the expression of alpha-spectrin from that SPTA1 allele [35,79,80]. This genotype
causes severe to moderately severe, most typically transfusion-dependent HS since birth, that
nevertheless responds well to splenectomy.
Rare cases of autosomal recessive SPTA1-associated disease with biallelic pathogenic variants
causing complete or almost complete alpha-spectrin deficiency may present with fatal hydrops
fetalis in the third trimester of pregnancy or with life-threatening anemia in utero if pregnancy
is closely monitored. These fetuses can survive to term with in-utero transfusions or if they are
delivered prematurely for another reason and receive transfusions in the neonatal period.
Characteristic for this disease is reticulocytopenia even when anemic, and the disease does not
respond to splenectomy, requiring either lifelong transfusions with chelation therapy or
treatment with hematopoietic stem cell transplant (HSCT) [35].
Band 4.2 deficiency due to EPB42 variants — Band 4.2 (also called protein 4.2) strengthens
the linkage between band 3 and ankyrin. EPB42-associated HS is an autosomal recessive
disease. The typical patient with band 4.2 deficiency is of Japanese ancestry [82]; however,
patients of other ethnic backgrounds have also been identified [83,84]. A number of missense
and splicing mutations, as well as a few small deletions, indels, and gross deletions, have been
reported [85-90]. Other cases of band 4.2 deficiency may be secondary to a variant in SLC4A1
(encoding band 3) that alters its binding with band 4.2 protein and/or its interactions with the
cytoskeleton [61,91-94]. As noted above, deficiencies of band 4.2 are rare causes of HS. (See
Changes in the RBC membrane — Most of the pathogenic variants that cause HS do so by
reducing the level of one or more RBC membrane proteins that link the cytoskeleton to the
overlying plasma membrane. It is also possible for HS variants to affect protein-protein binding
rather than protein abundance. (See 'Overview of the proteins and genes involved' above.)
Studies from animal models suggest that one of the mechanisms of secondary cytoskeletal
protein deficiencies involves aberrant sorting of these proteins during the enucleation stage of
RBC maturation (when the nucleus is extruded, certain proteins are expelled with the extruded
cell nucleus) [95].
The loss of these proteins results in reduced vertical associations between the cytoskeleton and
membrane, which in turn cause microvesiculation and progressive membrane loss, the central
abnormality that defines HS [96-98]. Loss of membrane reduces the ratio of RBC surface area to
volume, in turn creating progressively more spherical cells ( picture 2). (See "Red blood cell
membrane: Structure and dynamics", section on 'Surface area to volume ratio (SA/V)'.)
There is evidence that membrane loss is present as early as the reticulocyte stage; this
distinguishes HS from autoimmune hemolytic anemia (AIHA), in which typically only mature
RBCs become spherocytic due to membrane loss [99].
Two hypotheses have been advanced to explain how deficient production or incorporation of
these membrane proteins lead to vesiculation and membrane loss. In the first, spectrin
deficiency acts directly on the bilayer to create areas of weakness that allow membrane loss. In
the second, band 3 deficiency or dispersion causes vesiculation by reducing the integrity of the
lipid bilayer [100].
Some individuals with HS have abnormal RBC ion transport, the severity of which may depend
on the degree of band 3 (also known as anion exchanger 1 [AE1]) deficiency [101]. On the other
hand, all spherocytes demonstrate increased passive permeability to monovalent cations
(sodium and potassium) [101,102]. (See "Hereditary stomatocytosis (HSt) and hereditary
xerocytosis (HX)", section on 'Control of RBC solute and water content'.)
giảm khả năng biến dạng => cản trở di chuyển ở những vùng bị hạn chế của vi tuần hoàn, tán huyết trong lách và/hoặc thực
bào ở lách
Mechanisms of hemolysis — Spherocytes are prone to hemolysis. The mechanisms include
reduced deformability, which impairs passage through constricted regions of the
microcirculation, hemolysis within the splenic microenvironment, and/or phagocytosis by the
splenic red pulp macrophages, which may occur in response to splenic trapping [103,104].
Loss of spectrin appears to be especially correlated with the severity of hemolysis [105]; this is
seen in the extreme case of severe reticulocytopenia and hemolysis of nascent reticulocytes
within the bone marrow in cases of complete alpha-spectrin deficiency [35]. (See 'Beta spectrin
or alpha-spectrin deficiency due to SPTB or SPTA1 pathogenic variants' above.)
Once RBCs become spherocytic, successive phagocytosis during repeated passages through the
splenic cords (a process termed splenic conditioning) promotes further membrane loss and a
progressively more spheroidal shape ( picture 2). (See 'Changes in the RBC membrane'
above.)
This in turn further impairs passage through the narrow fenestrations of the splenic cords
[103,106]. The mechanics of passage through the splenic cords and the effect on spherocytes
has been simulated using a two-component RBC model [107]. In severe cases, reduced
membrane stability may contribute to mechanical RBC destruction.
In addition to phagocytosis, the spleen also exposes RBCs to an acidotic, oxidizing,

metabolically unfavorable environment. RBCs may also become depleted of 2,3-
bisphosphoglycerate (2,3-BPG; also called 2,3-diphosphoglycerate [2,3-DPG]), and in certain
cases, there may be methylation of membrane proteins (in spectrin deficiency but not in band 3
deficiency) [108].
Case reports have described individuals with the same familial variant who have different
severities of hemolysis (variable clinical penetrance). In some cases, this variability has been
attributed to concomitant variants in other genes that affect RBC structure and function. As an
example, in a family with mild autosomal dominant HS due to partial band 3 deficiency, one
family member had more severe clinical features than others, and this was attributed to an
exacerbating effect of a variant in PKLR, which encodes pyruvate kinase (PK) [109]. It was
speculated that low ATP levels from his partial PK deficiency increased the osmotic fragility of
his RBCs. A study from Germany found that PK activity in RBCs from patients with HS were
relatively low, particularly in reticulocytes [110]. Loss of membrane-associated PK was proposed
to be responsible and might contribute to the severity of HS. Further studies are needed.
As discussed below, splenectomy can virtually eliminate hemolysis and anemia in almost all
cases of HS, with the exception of the most severe forms due to complete or almost complete
alpha-spectrin or complete band 3 deficiency. The role of splenectomy in HS management is
discussed below. (See 'Splenectomy' below.)
EPIDEMIOLOGY
phổ biến ở chủng tộc ở Bắc Âu, 1/2000 -1/5000
Disease prevalence — HS is seen in all populations but appears to be especially common in

people of northern European ancestry. In these individuals, HS affects as many as 1 in 2000 to 1
in 5000 (prevalence, approximately 0.02 to 0.05 percent) [22,23,97,111].
The frequency is thought to be lower in individuals from other parts of the world such as Africa
and Southeast Asia, although comprehensive population survey data are unavailable.
In a 2006 study that tested 402 severely jaundiced neonates (requiring phototherapy), four (1
percent) were ultimately diagnosed with HS (ie, approximately 20 times more prevalent than in
the general population; approximately one-fifth as prevalent as acquired, immune-mediated
spherocytosis) [112]. Other causes of neonatal jaundice and the evaluation of a neonate
suspected to have HS are presented below. (See 'Neonates' below and 'Differential diagnosis'
below.)
https://www.uptodate.com/contents/hereditary-spherocytosis/print?search=spherocytosis&source=search_result&selectedTitle=1~58&usage_type=… 10/76
Frequency of different genetic variants — Cohort studies providing relative frequencies of

the genes contributing to HS pathogenesis in different populations include:
● In a study of 166 children with HS in Canada, a pathogenic variant was identified in 160 of
166 (97 percent) [48]. The percentages of pathogenic variants were seen:
• ANK1 – 49 percent
• SPTB – 33 percent
• SLC4A1 – 13 percent
• SPTA1 – 5 percent
● In a study of 113 patients with HS from 73 families in India, the variants identified included
de novo and dominantly inherited variants in the following genes [68]:
• SLC4A1 – 4 percent
Compound heterozygous variants in SPTA1 causing autosomal recessive disease were

identified in 6 percent.
● In a study of 95 patients in the Netherlands evaluated by next-generation sequencing

(NGS) performed in the University Medical Center Utrecht Laboratory, a pathogenic variant
was identified in 85 (89 percent) [113].
• SPTA1 – 36 percent, possibly representing a bias of ordering genetic testing in patients

with the severe phenotype of SPTA1-associated HS
● Another study identified autosomal recessive HS due to biallelic pathogenic variants EPB42
in individuals of Japanese ancestry [85,86]. Sporadic cases have also been described in
patients of European ancestry [83,84].
CLINICAL PRESENTATION
Bất kì độ tuổi và mức độ nặng khác nhau, có thể trong bào thai
Disease severity and age of presentation — HS can present at any age and with any severity,
with case reports describing a range of presentations from hydrops fetalis in utero through
diagnosis in the ninth decade of life [97,100,114-116].
The majority of affected individuals have mild or moderate hemolysis or hemolytic anemia and
a known family history, making diagnosis and treatment relatively straightforward [98].
Individuals with significant hemolysis may develop additional complications such as
jaundice/hyperbilirubinemia/cholelithiasis (typically exacerbated with concurrent Gilbert
syndrome), folate deficiency, or splenomegaly [117]. tán huyết nặng: vàng da/tăng Bili/sỏi mật, thiếu folat or lách to
Hemolytic anemia — A classification for HS has been developed based on the severity of
anemia and markers of hemolysis (reticulocyte count and bilirubin) [4,35,86,98,118].
Neonates frequently present with neonatal jaundice that is noted to rise in the first day of life,
posing a risk of kernicterus if not monitored and treated appropriately. However, they have a
normal hemoglobin at birth. Anemia ensues after two to three weeks as the normal neonatal
hyposplenism resolves; hemoglobin frequently decreases enough to require transfusion
[2,119].
Transfusion dependence in the first 9 to 12 months of life, when the erythropoietic response
may not be adequate, is not necessarily prognostic of the disease severity [120,121]. Infants
with an autosomal dominant form of HS based on family history and/or genetic evaluation who
require frequent transfusions during the first year of life may benefit from erythropoietin
administration [122]. Transfusion dependence beyond the first year of life is not expected for
autosomal dominant HS or the autosomal recessive HS due to EPB41 biallelic pathogenic
variants, but it is almost always the case for SPTA1-associated autosomal recessive HS. Red
blood cell (RBC) indices are described below. (See 'Initial testing' below.)
In older children and adults, the presentation may be that of an incidental finding of hemolysis,
hemolytic anemia, or spherocytes on the blood smear ( picture 2), or the individual may be
symptomatic with anemia, splenomegaly, pigment gallstones, or jaundice. Jaundice due to
severe hemolysis is less common after the newborn period, but scleral icterus is not rare,
especially when the patient also has Gilbert syndrome [117]. (See 'Older children and adults'
below.)
In some cases, co-inheritance of another disorder affecting RBC survival such as sickle cell
disease or thalassemia can influence the severity of anemia and make diagnosis more
challenging [118]. (See 'Evaluation' below.)
Exacerbations of anemia may also occur in certain settings:
● Infections – Infections that impair erythropoiesis in the bone marrow and thus diminish
the capacity to compensate for chronic hemolysis may lead to a period of aplasia. A
commonly cited cause of transient aplastic crisis is parvovirus B19 infection; other viral or
bacterial infections may also cause transient aplasia. This is because individuals with
chronic hemolysis are highly dependent on the accelerated production of new RBCs by the
bone marrow, and they can experience a rapid drop in hemoglobin level when the bone
marrow is unable to compensate for hemolysis.
In a series of individuals with hereditary hemolytic anemias who presented to the hospital
with acute parvovirus infection, common manifestations included fever, musculoskeletal
pains, and pancytopenia, while acute kidney injury was also reported, likely due to
inadequate supportive management [123]. If an individual with HS develops a precipitous
decline in hemoglobin level or reticulocyte count, testing for parvovirus infection is
recommended. (See "Clinical manifestations and diagnosis of parvovirus B19 infection".)
Infections may also exacerbate hemolysis, causing worsening of anemia even with
increased reticulocyte count and parallel increase of bilirubin and lactate dehydrogenase
(LDH). EBV or CMV infection, which typically cause splenomegaly ( table 1), may cause
increased splenic pooling of RBCs and/or increased hemolysis (hemolytic crisis) in patients
with HS or other underlying hereditary hemolytic anemias. (See "Splenomegaly and other
splenic disorders in adults", section on 'Splenomegaly'.)
● Nutrient deficiencies – Individuals who become deficient in folate, vitamin B12, or iron
may be unable to produce sufficient RBCs to compensate for those destroyed by
hemolysis. (See "Clinical manifestations and diagnosis of vitamin B12 and folate
deficiency" and "Iron deficiency in infants and children <12 years: Screening, prevention,
clinical manifestations, and diagnosis" and "Iron requirements and iron deficiency in
adolescents" and "Causes and diagnosis of iron deficiency and iron deficiency anemia in
adults".)
● Pregnancy – Anemia may worsen during pregnancy as the RBC mass and plasma volume
expand to meet the physiologic needs of the pregnancy. Attention to folic acid
supplementation is especially important during pregnancy to avoid increased risk of
neural tube defects in the fetus and superimposed megaloblastic anemia for the mother
[124,125].
Iron deficiency is rare in hereditary spherocytosis, as in all hereditary hemolytic anemias;

therefore, attention must be paid to avoid oral iron supplementation during pregnancy
when iron overload may actually be present [124,126]. (See 'Overview of treatment' below.)
Individuals who experience a decline from their baseline hemoglobin level and/or reduction in
baseline reticulocyte count are likely to require more frequent monitoring and/or additional
testing, details of which will depend on the associated symptoms and laboratory findings.
Complications of hemolysis — Common complications of hemolysis in individuals with HS

include neonatal jaundice, splenomegaly, and pigment gallstones, which are discussed in the
sections that follow. (See 'Neonatal jaundice' below and 'Splenomegaly' below and 'Pigment
gallstones' below.)
Rarely, hemolysis may be severe enough to cause extramedullary hematopoiesis and/or growth
delay, along with iron overload due to increased iron absorption and/or transfusions [127,128].
The majority of patients with HS are not thought to be in risk of iron overload [97]; however,
there are no extensive studies of older patients, and some cases with iron overload associated
with autosomal dominant HS have been reported [129].
Other rare complications that have been reported include leg ulcers, priapism, neuromuscular
disorders, cardiac disease, and gout; in some cases, these may represent coincidental rather
than causal associations [97,130,131].
Neonatal jaundice — HS may present in the neonatal period with jaundice and
hyperbilirubinemia, and the serum bilirubin level may not peak until several days after birth.
(See 'Disease severity and age of presentation' above.)
Some experts have proposed that HS is underdiagnosed as a cause of neonatal jaundice [132].
A requirement for phototherapy and/or exchange transfusion during this period is common
[97,120]. (See 'Neonates' below.)
Hyperbilirubinemia may be exacerbated by concomitant Gilbert syndrome. (See "Unconjugated

hyperbilirubinemia in neonates: Etiology and pathogenesis".)
Splenomegaly — Splenomegaly is rare in neonates but can often be seen in older children
and adults with HS [119]. Early reports of family studies found palpable spleens in over three-
fourths of affected members, but this may reflect a skewed population with the most severe
disease. In these studies, the relationship between disease severity and splenic size was not
linear [133].
There is no evidence of an increased risk of splenic rupture.
Indications for splenectomy in HS and possible complications are discussed below. (See
'Splenectomy' below.)
Pigment gallstones — Pigment (bilirubin) gallstones are common in individuals with HS and
may be the presenting finding in adults. Gallstones are unlikely before the age of 10 years but
are seen in as many as 50 percent of adults, especially those with more severe hemolysis [134].
Gallstones appear to be more common and tend to appear earlier in individuals with Gilbert
syndrome (inherited disorder of bilirubin glucuronidation) [117]. (See "Gilbert syndrome",

section on 'Long-term complications'.)
Obstructive jaundice or cholecystitis is treated similarly to that in individuals without HS. If

cholecystectomy is performed, it may be worthwhile to discuss whether splenectomy was also
planned, as the procedures could be combined; however, splenectomy should not be routinely
performed during cholecystectomy [118,135-137].
EVALUATION Thiếu máu tán huyết Coomb âm, và HC hình cầu/PMNB
When to suspect HS — The diagnosis of HS should be suspected in an individual with direct

antiglobulin test (DAT; Coombs test)-negative (non-immune) hemolytic anemia and spherocytes
on the peripheral blood smear. A positive family history of HS or negative testing for other
inherited hemolytic anemias increases suspicion for HS. Severe disease can present in the
neonatal period, whereas mild or compensated HS may not present until adulthood. (See
'Disease severity and age of presentation' above.) Giảm Hb, Haptoglobin.
Tăng HC lưới, LDH, Bilirubin
Typical findings of hemolytic anemia include low hemoglobin level, high reticulocyte count, high
lactate dehydrogenase (LDH) and bilirubin, and low haptoglobin. (See "Diagnosis of hemolytic
anemia in adults", section on 'Laboratory confirmation of hemolysis'.)
If hemolysis is severe, the patient may have jaundice (including neonatal jaundice). If
compensation is insufficient (if the bone marrow cannot produce new red blood cells [RBCs]
with sufficient rapidity to compensate for hemolyzed RBCs), there may be symptoms of anemia.
(See "Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis", section on
'Increased production'.)
HS is a non-immune form of hemolysis; the DAT is negative. (See "Overview of hemolytic

anemias in children", section on 'Intrinsic hemolytic anemias' and "Diagnosis of hemolytic
anemia in adults", section on 'Immune versus non-immune'.)
Findings that suggest an alternative diagnosis include prior normal complete blood counts
(CBCs) and hemolysis markers. It must be noted that 3 to 11 percent of autoimmune hemolytic
anemias may be DAT-negative, depending on the sensitivity of the assay [138,139]. A high-index
of suspicion for DAT-negative autoimmune hemolytic anemia (AIHA) must be maintained for a
patient presenting with hemolytic anemia with no prior personal and family history, especially
with microspherocytes on the smear and other evidence of immune dysregulation [140].
Evaluation of the peripheral blood smear is very helpful; obvious RBC abnormalities may
suggest a different type of hemolytic anemia (eg, stomatocytes, ovalocytes, target cells, sickle
cells). (See "Evaluation of the peripheral blood smear", section on 'Permutation in shape'.)
XN: + CTM (MCHC, RDW), PMNB (HC hình cầu, HC bất thường), HCL, Coombs DAT (-)
Initial testing + Bilan tán huyết: BiliGT, LDH, Haptoglobin
All patients — Some aspects of the initial evaluation differ in neonates versus older children
and adults since affected neonates tend to have more severe disease and less useful laboratory
parameters. (See 'Neonates' below.)
However, the following are appropriate in virtually all individuals:
● CBC and RBC indices – All individuals with suspected HS based on family history, neonatal
jaundice, or other findings should have a complete blood count (CBC) with reticulocyte
count and RBC indices. The mean corpuscular hemoglobin concentration (MCHC) is often
the most useful parameter for assessing spherocytosis; an MCHC ≥36 g/dL is consistent
with spherocytes. A normal mean corpuscular volume (MCV) is expected, with a wide
(increased) red cell distribution width (RDW); significant reticulocytosis may increase the
MCHC>=36
MCV. MCV bt/tăng, RDW tăng
● Blood smear review – All individuals with suspected HS should have a blood smear
reviewed by an experienced individual. RBC parameters to be assessed include the
presence and abundance of spherocytes, other abnormal RBC shapes, and the degree of
polychromatophilia, which reflects reticulocytosis. PMNB: HC hình cầu, HC dạng bất thường, bắt màu nhiều,
Tăng HC lưới
● Hemolysis testing – Testing for hemolysis is also appropriate in all patients. This includes
lactate dehydrogenase (LDH), indirect bilirubin, haptoglobin, and reticulocyte count.
Findings consistent with hemolysis include increased LDH and indirect bilirubin, decreased
Bilan tán huyết: Tăng LDH, BiliGT
or absent haptoglobin, and an elevated reticulocyte count. Giảm haptoglobin
● Coombs testing – If hemolysis is present, a DAT should be done to evaluate for the
possibility of immune-mediated hemolysis, which may be due to hemolytic disease of the
fetus and newborn (HDFN) in neonates or autoimmune hemolytic anemia (AIHA) in older
children and adults.
The results of testing may also be useful to the transfusion service if transfusion is
indicated. The DAT in HS is negative. It should be noted that 3 to 11 percent of AIHAs may
also be DAT-negative, depending on the sensitivity of the assay [138,139]. Therefore, a
high-index of suspicion for DAT-negative AIHA is indicated for a patient presenting with
hemolytic anemia with no prior personal and family history, especially with presence of
microspherocytes on the smear and other evidence of immune dysregulation [140].
Our approach to the evaluation is consistent with a 2011 guideline (published in 2012) from the
British Committee for Standards in Haematology (BCSH) on the diagnosis of HS and a 2015
guideline from the International Council for Standardization in Haematology (ICSH) on non-
immune hereditary RBC membrane disorders [118,141].
Neonates — Neonates with severe hemolysis due to HS may present with neonatal jaundice.
(See 'Disease severity and age of presentation' above.)
The evaluation of a neonate with suspected HS depends on whether a parent is known to have
HS.
● If an infant with hyperbilirubinemia or other findings of non-immune hemolytic anemia

has a known family history of HS, then the likelihood of HS is high, and we rely heavily on
the RBC indices. As noted above, an MCHC ≥36 g/dL is highly suggestive of HS. (See
'Clinical presentation' above.)
● If an infant with hyperbilirubinemia or hemolytic anemia does not have a known family
history of HS, then a number of other possible diagnoses must be considered. (See
'Differential diagnosis' below.)
Appropriate therapy should not be delayed while determining the underlying cause; likewise,
the importance of making the diagnosis of HS should be emphasized regardless of the
management interventions needed. Hemolytic anemia with a negative DAT and a high MCHC
(eg, ≥36 g/dL) is consistent with HS but must be considered in the context of the entire clinical
picture. (See 'Confirmatory tests' below and "Unconjugated hyperbilirubinemia in neonates:
Etiology and pathogenesis" and "Unconjugated hyperbilirubinemia in term and late preterm
newborns: Screening".)
Neonates with HS tend to have an elevated MCHC (typical range in HS, 35 to 38 g/dL) [119]. This
is a useful discriminator between HS and hemolytic disease of the fetus and newborn (HDFN)
because HDFN RBCs tend to have MCHC in the range of 33 to 36 g/dL [132].
Spherocytes on the blood smear are helpful if present, but up to one-third of neonates with HS
do not have prominent spherocytes, and some neonates without HS have spherocytes [119]. In
addition, it may be difficult to assess spherocytes on the peripheral blood smear in a neonate,
either because neonates with HS may have fewer spherocytes or because spherocytic cells are
often present after birth in neonates without HS [141].
If the infant is well, it is reasonable to postpone testing until approximately six months of age or
older, at which time the RBC morphology will be easier to assess [118]. If there is greater
urgency to establish a diagnosis (eg, severe anemia or hyperbilirubinemia), specialized testing
may be used. (See 'Confirmatory tests' below.)
Older children and adults — As noted above, HS may be suspected in a patient of any age
who has evidence of hemolysis (eg, elevated serum LDH, elevated indirect bilirubin, reduced
haptoglobin, increased reticulocyte count) or hemolytic anemia that is DAT-negative and not
explained by another condition.
HS may also be suspected in an individual who presents with a complication of hemolysis, such
as splenomegaly, pigmented gallstones, or an abrupt drop in hemoglobin level when the bone
marrow cannot compensate for hemolysis (eg, during a viral illness, pregnancy, or other
condition). In such cases, a CBC will be obtained and RBC indices will be available; the
reticulocyte count should also be measured if not done already.
Evidence consistent with HS as the likely diagnosis in an older child or adult include the
following:
● Positive family history of HS, although this is not always present as some cases arise as de
novo pathogenic variants and not all individuals will have a complete family history
available.
● Chronic hemolytic anemia, although in mild cases, there may be chronic compensated
hemolysis without anemia. The typical reticulocyte count in older children and adults with
HS is approximately 5 to 20 percent, but it may be as high as 20 to 30 percent in severe
cases.
● Jaundice and/or splenomegaly, although these may be absent if the hemolysis is mild.
● Spherocytes ( picture 2) on the peripheral blood smear. The percentage of spherocytes

is variable. Pathogenic variants in certain genes have been associated with specific
spherocyte morphologies, although the diagnostic value of these findings has not been
rigorously tested [5,69,70,142,143] (see 'Genetics' above):
• Anisocytic spherocytes – Ankyrin deficiency

• Pincered or mushroom-shaped spherocytes – Band 3 deficiency
• Acanthocytic spherocytes – Beta spectrin deficiency
• Dense and irregularly shaped cells – Alpha spectrin deficiency
• Ovalocytes and occasional ovalostomatocytes – Protein 4.2 deficiency
● RBC indices consistent with spherocytosis (eg, MCHC >36 g/dL; normal MCV with wide red
cell distribution width [RDW]). The MCV and RDW may be increased by greater degrees of
reticulocytosis in older children and adults; thus, the MCHC is the most useful of the RBC
indices.
The combination of increased MCHC and increased RDW further improves diagnostic
performance [144]. If reticulocyte indices are available, a higher-than-average reticulocyte
MCHC and a low reticulocyte MCV are also consistent with HS ( table 2) [118].
In the appropriate clinical setting, these observations may be sufficient to screen for a diagnosis
of HS. (See 'Diagnosis' below.)
In cases that are unclear or if there are questions about the prognosis or if splenectomy is
being considered, additional diagnostic confirmation is needed, especially to avoid
misdiagnosis of hereditary xerocytosis as HS. The following specialized testing can be pursued.
(See 'Confirmatory tests' below.)
Confirmatory tests — A number of tests are available for confirming the diagnosis of HS.
● EMA binding – Eosin-5-maleimide (EMA) binding is a good and widely available test for HS
diagnosis; it detects loss mainly of band 3 and Rh-related proteins from the RBC
membrane, using EMA, an eosin-based fluorescent dye, that binds to those RBC
membrane proteins [145].
The mean fluorescence of EMA-labeled RBCs from individuals with HS is lower than
controls, and this reduction in fluorescence can be detected in a flow cytometry-based
assay, as illustrated in the figure ( figure 3). The reduction in EMA binding is observed in
RBCs when HS is due to band 3 deficiency or to deficiencies in other proteins such as
ankyrin or spectrin, since the common characteristic in HS is loss of membrane along with
band 3 complexes [146]. Two case series of individuals with HS have found the EMA
fluorescence in individuals with HS to be approximately two-thirds that of controls
[145,147]. Samples can be stored and tested; one of the studies also analyzed the effect of
delayed testing and found that samples stored for 24 hours in the darkness gave similar
results to those tested immediately [145].
Advantages of EMA binding include its high sensitivity; rapid turnaround time
(approximately two hours); and need for only a minimal amount of blood (a few
microliters), which is especially advantageous for testing neonates [148-150]. EMA testing
can also be used to evaluate for HS-RBCs in a specimen from a patient who has recently
received a transfusion [151]. In various studies, the sensitivity and specificity of the test to
diagnose HS versus normal RBCs appear to be in the ranges of 93 to 96 and 93 to 99

percent, respectively [148,152-154]. It is important in testing neonatal RBCs to compare
the results of EMA binding to control samples from age-matched controls [155].
However, when EMA results for HS are compared with those for other RBC membrane
disorders, the specificity of the test declines. EMA binding is also decreased (ie, the test is
considered positive) in other hemolytic anemias with loss of membrane associated with
band 3 complexes, such as hereditary pyropoikilocytosis, spherocytic
elliptocytosis/pyropoikilocytosis, Southeast Asian ovalocytosis (SAO), autoimmune
hemolytic anemia, as well as congenital dyserythropoietic anemia (CDA) type II
[147,152,156]. False-negative results may be seen in mild cases of HS. (See 'Differential
diagnosis' below.)
● Osmotic fragility – Osmotic fragility testing (OFT) is a traditional, specialized test for HS,
based on the fact that spherocytic RBCs have reduced surface area to volume (SA/V) ratio.
In this test, fresh RBCs are incubated in hypotonic buffered salt solutions of various
osmolarities, and the fraction of hemoglobin released (due to hemolysis) is measured. The
test takes advantage of the increased sensitivity of spherocytes to hemolysis due to their
reduced SA/V ratio ( figure 4). Incubation of patient samples for 24 hours prior to testing
may accentuate osmotic fragility and improve diagnostic yield.
The OFT has relatively low sensitivity and specificity. It fails to identify a significant number
of individuals with HS, and, particularly in the newborn, it may be positive in other
conditions including immune hemolytic anemia, hemolytic transfusion reactions, RBC
enzyme deficiencies such as glucose-6-phosphate dehydrogenase (G6PD) deficiency, and
unstable hemoglobin variants [141]. In one series of 86 individuals with HS, only 57 (66
percent) had positive osmotic fragility testing [157].
● Osmotic gradient ektacytometry – Osmotic gradient ektacytometry (OGE) is the

reference method to evaluate RBC membrane disorders [158,159]. It offers accurate (with
100 percent assay sensitivity) diagnosis of HS and excellent specificity in differential
diagnosis between the various RBC membrane disorders, including hydration defects
( figure 3) [2,81,156]. The assay evaluates the deformability of RBCs as they are
subjected to constant shear stress in a medium of increasing osmolality in a laser
diffraction viscometer. The testing has become more accessible over the last decade with
the commercial availability of a new generation ektacytometer) [156,160].
Limitations of OGE include its decreased sensitivity after recent transfusions, as with all
phenotypic tests that evaluate RBCs as a population. Warm AIHA with a significant number
of microspherocytes and CDA-II may produce an ektacytometry curve resembling HS

[2,81].
● Glycerol lysis – The glycerol lysis test (GLT) and the acidified GLT (AGLT) are modifications
of the OFT that add glycerol (in the GLT) or glycerol plus sodium phosphate (to lower the
pH to 6.85, in the AGLT) to the hypotonic buffered salt solutions in which the patient's
RBCs are incubated [111,141]. Like EMA, OFT, and OGE, these tests may also be positive in
acquired spherocytosis conditions such as AIHA.
The "pink test" is a modification of the GLT in which the final extent of hemolysis is
measured in a blood sample incubated in the glycerol solution at pH 6.66 [161]. A further
modification has been proposed (the direct pink test) in which the test sample is obtained
from fingerprick (or heel puncture in newborns), rather than venipuncture, and incubated
directly in the glycerol solution; this requires only a few microliters of blood [162].
● Cryohemolysis – In the cryohemolysis test, RBCs are suspended in a hypertonic solution,

briefly heated to 37°C, then cooled to 4°C for 10 minutes [163]. Ease of performance and
the wide separation in degree of hemolysis between spherocytes and normal cells are two
attractive features of this test [164].
The last two tests (glycerol lysis and cryohemolysis) have limited availability in the United States.
The relative performance of these tests was evaluated in a 2012 study that tested samples from
150 individuals known to have HS [147]. Test sensitivities were as follows:
● AGLT – 95 percent
● EMA binding – 93 percent
● Pink test – 91 percent
● Osmotic fragility, incubated – 81 percent
● Osmotic fragility, fresh – 68 percent
● GLT – 61 percent
Combined testing with EMA binding and AGLT had a sensitivity of 100 percent; combined
testing with EMA binding and pink test had a sensitivity of 99 percent; and EMA binding plus
osmotic fragility (incubated or fresh) had a sensitivity of 95 percent [147].
Direct comparison of EMA testing versus OGE identified the benefits of EMA testing as a fast,
widely available screening test for HS but also indicated the advantage of OGE to differentiate
HS from other RBC membrane disorders [156]. When the question is the differentiation
between xerocytosis and spherocytosis, before proceeding to splenectomy, OGE as well as

genetic evaluation for the pathogenic gene variant is preferable [2,81,156].
These results demonstrate that no single phenotypic testing has 100 percent sensitivity and
specificity to accurately identify all individuals with HS, especially if the patient has been recently
transfused. Test results should be compared with results of a normal control of similar age,
evaluated in parallel with the patient's specimen, as well as with the reference range for many
normal samples evaluated by the specific laboratory. Diagnostic yield may be improved by using
two tests and by taking into account the personal and family history of the patient and
evaluating the blood smear and RBC indices.
These tests can also be positive in other conditions, and the results cannot be interpreted in
isolation. If a positive test is not consistent with the clinical picture or findings on the peripheral
blood smear, laboratory personnel or a consulting hematologist with expertise in interpreting
these tests should be consulted [118].
Specialized testing for selected cases (including genetic testing) — In certain atypical cases
in which further characterization of the RBC cytoskeletal/membrane proteins is needed,
research-based gel electrophoresis can be done using RBC ghosts.
Clinical grade next generation DNA sequencing is available by several academic and commercial
laboratories to evaluate for the genetic cause of an RBC membranopathy or more broadly of a
hereditary hemolytic anemia. Identifying a familial disease variant may be useful for prognosis
and genetic counseling. (See 'Testing relatives; reproductive testing and counseling' below.)
More importantly, misdiagnosis of hereditary xerocytosis (HX) as spherocytosis has to be

avoided, since splenectomy is contraindicated in HX especially, because it predisposes patients
to life-threatening venous and arterial thromboembolic complications, and it does not improve
hemolysis either [165-167].
Resources for genetic testing are listed on the Genetic Testing Registry website.
Certain academic laboratories have a special interest or ability in performing this testing and
may be contacted for further discussions. As examples:
● Cincinnati Children's Molecular Genetics Laboratory:
• Website – www.cincinnatichildrens.org/moleculargenetics
• Phone – (513) 636-4474
● Blood Disease Reference Laboratory Program at Yale University:
• Website – www.medicine.yale.edu/pathology/clinical/mdx/
• Phone – (203) 737-1349
● Mayo Medical Laboratories:
• Website – https://www.mayomedicallaboratories.com/customer-
service/contacts.html - DAT âm
- MCHC tăng
• Phone – (800) 533-1710 - Tiền căn gđ
- HC hình
• Email – mml@mayo.edu (United States) or mliintl@mayo.edu (international) cầu/PMNB
=> EMA bliding,
OGE
Diagnosis — The diagnosis of HS is made in an individual who presents with DAT-negative
hemolysis, an increased MCHC, a positive family history for HS, and/or spherocytes on the
peripheral blood smear, by finding a positive result from one or more confirmatory tests such
as EMA binding, osmotic fragility, or osmotic gradient ektacytometry (OGE). Specialized testing
is especially important if splenectomy is being considered. Specialized testing may be omitted if
definitive diagnosis is unlikely to alter management (eg, if hemolysis is mild and childbearing is
not planned) or in resource-limited areas of the world [118]. (See 'Confirmatory tests' above.)
For an individual with a strong suspicion of HS and negative or equivocal testing by EMA
binding, for whom accurate diagnosis was especially important (eg, due to a previous affected
child), positive results from genetic testing are confirmatory for HS. Genetic testing is available
in several specialized laboratories. (See 'Specialized testing for selected cases (including genetic
testing)' above.)
This testing is similar to that described in published guidelines [118,141]. However, we are more
likely to order confirmatory testing in all patients except those in resource-limited settings or
those who do not have access to specialized testing for other reasons, as treatment for HS may
differ from other conditions (eg, splenectomy is often used in HS but should be avoided in
hereditary stomatocytosis). (See 'Splenectomy' below.)
Differential diagnosis — The differential diagnosis of HS includes a number of other hemolytic

anemias with spherocytes on the peripheral blood smear:
● Other inherited hemolytic anemias – Other inherited RBC membrane disorders include
hereditary elliptocytosis (HE) ( picture 3) and elliptocytosis variants (hereditary
pyropoikilocytosis [HPP]) ( picture 4), overhydrated and dehydrated hereditary
stomatocytosis (OHSt and DHSt respectively); DHSt is also known as hereditary xerocytosis
(HX) ( figure 5). RBC enzyme disorders include glucose-6-phosphate dehydrogenase
(G6PD) deficiency, pyruvate kinase (PK) deficiency, and other rarer metabolic disorders.
Like HS, these present with variable degrees of anemia and hemolysis and can be
diagnosed at any age. Unlike the other disorders, G6PD deficiency (except for the disease
due to rare class I variants) typically presents with episodes of hemolytic crisis after
exposure to oxidant drugs rather than chronic hemolysis. Unlike the other membrane
disorders, which each have distinctive morphologies on the blood smear, and the enzyme
disorders, which typically have nonspecific findings (eg, mild reticulocytosis), HS is
characterized by spherocytosis as the predominant morphology. (See "Overview of
hemolytic anemias in children", section on 'Intrinsic hemolytic anemias' and "Diagnosis of
hemolytic anemia in adults", section on 'Intracorpuscular'.)
It is especially important to distinguish between HS and HSt because HS is generally

helped by splenectomy, whereas in HSt, splenectomy should be avoided because it
predisposes patients to life-threatening venous and arterial thromboembolic
complications, and it does not improve hemolysis either [165-167]. (See 'Decision to
pursue splenectomy' below.)
● Neonatal alloimmune hemolytic anemia – Neonatal alloimmune hemolytic anemia,

historically known as hemolytic disease of the fetus and newborn (HDFN), is most
frequently caused by ABO or Rh incompatibility between fetal RBCs and the mother's
immune system; maternal antibodies cross the placenta and recognize the foreign (to the
mother) fetal RBC antigens, leading to alloimmune hemolysis. Neonates may present with
severe jaundice and anemia requiring aggressive treatment, and like in HS, HDFN can be
associated with abundant spherocytes on the blood smear. Unlike HS, HDFN is a transient
condition that resolves after the maternal antibodies are cleared, and HDFN is
characterized by positive DAT testing, detecting the maternal alloantibodies on fetal RBCs,
and demonstrating an immunologically significant discordance between maternal and
neonatal blood type. (See "Alloimmune hemolytic disease of the newborn: Postnatal
diagnosis and management".)
● Infantile pyknocytosis – Infantile pyknocytosis is a disorder of unknown etiology in which

RBCs become hyperdense and dehydrated [168]. Like HS, this condition presents in
neonates with anemia and an increased mean corpuscular hemoglobin concentration
(MCHC). Unlike HS, the RBCs have irregular borders and varying numbers of projections,
and the condition resolves spontaneously during the first year of life (typically, three to
nine months after birth) with no other intervention than supportive care (such as
treatment of neonatal jaundice with phototherapy and PRBC transfusions as needed).
● Congenital dyserythropoietic anemia (CDA) – CDA type II is an autosomal recessive rare

hereditary anemia caused by biallelic SEC23B pathogenic variants. SEC23B encodes a
member of the cytoplasmic coat protein II (COPII) complex, which is implicated in

intracellular vesicle trafficking in eukaryotic cells, and loss of its function disturbs
erythropoiesis. Like HS, some individuals may have significant hemolysis and/or
splenomegaly, and like HS, some specialized tests such as EMA binding and OGE may be
positive; this is because glycosylation and appropriate positioning of band 3 in the RBC
cytoskeleton is compromised [169]. Unlike HS, individuals with CDA-II have the
characteristic finding of binucleate and multinucleate erythroblasts in the bone marrow,
and the reticulocyte count is typically lower, indicating ineffective erythropoiesis, which in
severe phenotypes tend to be associated with significant iron overload, disproportionate
to the history of RBC transfusions [118]. (See "Overview of causes of anemia in children
due to decreased red blood cell production", section on 'Congenital dyserythropoietic
anemia'.)
● Autoimmune hemolytic anemia (AIHA) – AIHA is caused by increased RBC destruction

(hemolysis) triggered by autoantibodies directed against self-RBC antigens, with or
without complement activation. It is a rare disease with an incidence of 1 to 3 per 100,000
people per year [139]. Warm AIHA associated with an underlying disorder such as systemic
lupus erythematosus (SLE) or without an underlying disorder is more common than cold
AIHA, which is typically triggered by an infection such as infectious mononucleosis. Like
HS, patients can have anemia and/or hemolysis of variable severity and abundant
spherocytes on the peripheral blood smear. Unlike HS, in AIHA, DAT is typically positive,
the family history is negative for hemolytic anemia, and prior complete blood counts
(CBCs) will show a normal hemoglobin level and reticulocyte count. (See "Autoimmune
hemolytic anemia (AIHA) in children: Classification, clinical features, and diagnosis" and
"Warm autoimmune hemolytic anemia (AIHA) in adults" and "Cold agglutinin disease".)
MANAGEMENT
Ngăn ngừa hay hạn chế các biến chứng của thiếu máu/tán huyết mạn
Overview of treatment — As with most inherited hemolytic anemias, treatment is directed at
preventing or minimizing complications of chronic hemolysis and anemia. There are no specific
treatments directed at the underlying red blood cell (RBC) membrane abnormality.
Monitoring — The frequency of patient monitoring depends on disease severity and

symptoms. (See 'Disease severity and age of presentation' above.)
Babies born to families with history of HS need careful monitoring for hyperbilirubinemia rising
already within the first day of life. Anemia ensues typically two to three weeks after birth as the
normal neonatal hyposplenism resolves, and hemoglobin frequently decreases enough to

require transfusion [2,119].
Once a baseline has been established, an annual visit is sufficient for a child with mild
hemolysis, with closer monitoring during viral or other infections that might cause more severe
anemia [118]. Growth should be monitored, and patients and/or families should be informed
about the possible risk of transient aplastic crisis, including the symptoms and the need to seek
medical attention. Adults with mild disease may receive routine medical and preventive care;
those with more severe hemolysis may require more frequent monitoring, with the interval
depending on their specific needs. (See 'Hemolytic anemia' above.)
Supportive measures — General supportive measures may include the following, depending
on disease severity:
● Treatment of hyperbilirubinemia – If a neonate is suspected of having HS (eg, based on

positive family history and neonatal jaundice), supportive treatment should be initiated for
the neonatal hyperbilirubinemia and/or anemia without awaiting diagnostic confirmation.
Therapy for hyperbilirubinemia may range from simple phototherapy to exchange
transfusion [119]. (See "Unconjugated hyperbilirubinemia in term and late preterm
newborns: Initial management".)
● Folic acid – Folic acid supplementation is appropriate for those with moderate to severe
hemolysis and/or during pregnancy. This is based on an increased requirement for folate
in RBC production. There are no clinical trials investigating the role of folic acid treatment.
However, observational studies that documented megaloblastic anemia in a small number
of patients with HS were performed before the institution of routine folic acid
supplementation of grains and cereals [98]. This, coupled with the low cost and minimal
toxicity of folic acid, make it an attractive and simple therapy to recommend.
The typical dose for infants up to 6 to 12 months of age is 0.4 mg daily, while thereafter 1
mg/day is typically prescribed for those with moderate to severe hemolysis. Individuals
with HS of any severity who are planning to be pregnant and during pregnancy should
receive a dose of 2 to 4 mg/day. (See "Preconception and prenatal folic acid
supplementation".)
For individuals with mild hemolysis who have normal intake of fresh fruits and vegetables
(or folic-acid-supplemented grains), daily folic acid is not required, but for those who place
a high value on avoiding folate deficiency, which could cause worsening anemia, taking
daily folic acid (on the typical dose of 1 mg daily) is safe and inexpensive, and there are
essentially no side effects or contraindications.
● Erythropoietin – Erythropoietin (Epo) may be helpful in reducing the need for transfusion
in some infants [118,122]. Typically, this can be discontinued around the age of nine
months. In one study, the use of recombinant human Epo (1000 international units/kg per
week) with iron supplementation obviated the need for transfusion in 13 of 16 infants with
HS and severe anemia due to inadequate reticulocytosis during the first months of life
[122]. As the infants grew and began to mount an adequate erythropoietic response, the
Epo dose could be tapered and discontinued before the age of nine months.
● Considerations related to splenomegaly – There are no special restrictions (eg, no

activity limitations) on children with splenomegaly due to HS [118]. However, those with an
unusually large spleen should be made aware of the risk of splenic rupture during contact
sports. (See "Splenomegaly and other splenic disorders in adults", section on 'Sports
participation and fall risk'.)
Transfusions — Blood transfusion is often required in infancy, even in mild autosomal

dominant HS. The transfusion requirement in the first months of life does not necessarily
predict a severe phenotype. Transfusions may be needed in older children and adults in other
settings (eg, aplastic or hemolytic crisis with infections, pregnancy). Typical hemoglobin
thresholds for transfusion depend on the age of the patient, symptoms, and comorbidities.
In autosomal dominant HS and in most cases of autosomal recessive EPB42-associated HS,

transfusions usually are not required on a chronic basis or for a long enough time to cause iron
overload. In contrast, most patients with autosomal recessive SPTA1-associated HS are
transfusion-dependent until splenectomy is performed (if appropriate). (See 'Splenectomy'
below.)
● Infants – Many infants may require transfusions for anemia, and some may need
exchange transfusion for rapidly increasing hyperbilirubinemia. Older children with
autosomal dominant HS of mild or moderate severity may tolerate a hemoglobin as low as
7 g/dL without transfusion if reticulocyte count is increasing and this is a temporary
anemia exacerbation. However, chronic anemia with Hgb <7 g/dL is typically due to severe
autosomal recessive HS caused by SPTA1 (or more rarely ANK1 biallelic variants);
inadequate transfusion and chronic anemia in those cases is frequently associated with
growth delay and iron overload due to ineffective erythropoiesis. (See "Red blood cell
transfusion in infants and children: Indications".)
● Adults – Adults may require transfusions for anemia, with thresholds determined by their
clinical status, as discussed in detail separately. (See "Indications and hemoglobin
thresholds for RBC transfusion in adults".)
● Aplastic crisis – Individuals with an aplastic crisis due to parvovirus infection or other
bone marrow insult may require transfusions if they have a decreasing hemoglobin level
without a robust reticulocytosis. The usual course of parvovirus-associated anemia is
spontaneous resolution within a few days or weeks. Infected individuals are monitored
with twice-weekly complete blood counts (CBCs) and reticulocyte counts to determine the
expected hemoglobin nadir and the need for transfusion. (See "Treatment and prevention
of parvovirus B19 infection", section on 'Transient aplastic crisis'.)
Consideration of transfusional iron overload typically occurs after transfusion of >15 to 20 units
of RBCs (>10 units in smaller children). Adults with mild hemolysis may have a slight increase in
iron absorption, and if this occurs in the setting of hereditary hemochromatosis, which is
common, iron overload may occur. Screening for iron overload, management, and related
subjects are discussed separately. (See "Approach to the patient with suspected iron overload",
section on 'Transfusional iron overload'.)
Splenectomy
Decision to pursue splenectomy — Decisions regarding splenectomy must take into account
the severity of hemolysis, age of the patient, and the potential perioperative and post-
splenectomy long-term complications [118,136,165]. For those with relatively severe hemolysis,
splenectomy is effective at improving anemia.
Other considerations include:
● Diagnostic confirmation – It is important to confirm that the diagnosis is HS rather than

another inherited hemolytic anemia such as hereditary stomatocytosis (HSt), for which
splenectomy is neither safe nor effective. (See 'Differential diagnosis' above and
"Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)", section on
'Management'.)
● Type of HS (genotype) – Patients with SPTA1-associated autosomal recessive HS with the

most common genotype of a null SPTA1 variant in trans to the Low Expression PRAgue
(alpha-LEPRA) allele c.4339-99C>T are expected to have transfusion-dependent severe HS
that will respond well to splenectomy [35,79,80].
The use of splenectomy in individuals with moderate disease is individualized. We are

more likely to advise splenectomy for individuals with more severe hemolysis and/or
greater symptoms (eg, abdominal symptoms related to splenomegaly, distress related to
jaundice) or for those with growth delays or skeletal changes related to extramedullary
hematopoiesis.
In contrast, the most severe cases with HS due to complete alpha-spectrin or band 3
deficiency do not respond to splenectomy, and they require either lifelong chronic
transfusions and chelation or hematopoietic stem cell transplantation (HSCT). (See 'Beta
spectrin or alpha-spectrin deficiency due to SPTB or SPTA1 pathogenic variants' above.)
For children with HS who remain transfusion-dependent after one year of age, we
recommend that genetic diagnosis should be pursued to understand the cause and
prognosis and assist with management decisions. Genetic evaluation before planning for
splenectomy will also assist to avoid misdiagnosis of hereditary xerocytosis, for which
splenectomy will not be safe or effective. (See 'Specialized testing for selected cases
(including genetic testing)' above and 'Differential diagnosis' above.)
Autosomal dominant forms of HS generally are not transfusion-dependent after infancy. If

the genotype is that of one of the forms of autosomal dominant HS, further evaluation
needs to be performed to investigate for comorbidities that would make an autosomal
dominant HS present as a transfusion-dependent disease after infancy. (See 'Inheritance
patterns' above.)
● Ideal age – Ideally, splenectomy is delayed until the individual is >5 years of age to reduce
the likelihood of sepsis due to absent splenic function [118]. It is better to plan for a total
splenectomy after the age of five years and after completing the pre-splenectomy
immunizations for encapsulated bacteria at that age when the spleen is considered
mature enough to mount an optimal response to those immunizations.
Until the age of five years, the patient would likely benefit from a plan for chronic
transfusions to avoid growth delay and decrease stress erythropoiesis; monitoring for iron
overload and appropriate chelation treatment are used to avoid exacerbation of growth
delay by iron overload [170]. (See 'Transfusions' above.)
● Partial versus total splenectomy – In children younger than five years of age for whom
chelation is not successful, or if the family/caregivers prefer to avoid chronic transfusions,
consideration may be given to partial splenectomy after three years of age. All of the
appropriate pre-splenectomy immunizations should be completed prior to partial
splenectomy, with the plan to repeat them after five years of age, in case of suboptimal
response. A successful partial splenectomy reduces the risk of sepsis from encapsulated
bacteria compared to total splenectomy, and in some patients, partial splenectomy may
serve as a long-term treatment, even for autosomal recessive HS. (See 'Operative
techniques' below and "Elective (diagnostic or therapeutic) splenectomy", section on
'Partial splenectomy'.)
● Gallstone disease – Individuals with symptomatic gallstone disease who require

cholecystectomy should be evaluated for the possible role of simultaneous splenectomy,
but this should only be pursued if clinically indicated (eg, symptomatic hemolytic anemia
and/or severe complications of hemolysis). Simultaneous cholecystectomy can be
performed if gallstones are also present. (See 'Pigment gallstones' above and 'Gallstones'
below.)
Some individuals with mild hemolysis may pursue splenectomy as a means of reducing
gallstone formation, but for most individuals, the risks of splenectomy exceed the possible
benefit [171]. (See 'Complications' below.)
● Splenic embolization – In patients for whom splenectomy is appropriate but surgery is

refused or contraindicated, partial splenic embolization has been employed, with
anecdotal reports of success [172].
Our approach is consistent with a 2011 guideline from the British Committee for Standards in
Haematology (BCSH) and a 2017 guideline from the European Hematology Association (EHA)
[118,165].
Supporting evidence for splenectomy — There are no randomized trials comparing

splenectomy with expectant management. Observational evidence to support the efficacy of
both total and partial splenectomy includes the following:
● A 2016 series followed 79 individuals with HS after undergoing partial splenectomy at a

single institution in France [173]. The indications for splenectomy were transfusion
dependence or severe anemia in 39 and other symptoms (fatigue, gallstones, icterus) in
40. The mean age for splenectomy was 4.3 years for those who were transfusion-
dependent and 11 years for those with symptoms of anemia. The procedure involved
removal of 85 to 95 percent of splenic tissue using an open approach, with concurrent
cholecystectomy if gallstones were present.
At a mean of 11 years of follow-up, all patients but one had a significant improvement in
hemoglobin level (mean increase, 0.97 g/dL) and reduction in number of transfusions
(from 3.1 to 0.2 per patient per year), a benefit that remained stable or continued to
improve over the course of 10 years. A composite endpoint of no symptoms from anemia
was documented in 69 of the children (87 percent) and 65 were transfusion-free.
Regrowth of the splenic remnant was common, and 21 patients (27 percent) underwent
reoperation with total splenectomy, 49 percent for a significant decrease in hemoglobin
and 51 percent for other symptoms related to splenomegaly or hemolysis. The typical
interval between the initial partial splenectomy and the subsequent total splenectomy was
seven to nine years. Of the 46 who did not undergo concomitant cholecystectomy, 16 (35
percent) developed gallstones, typically several years after splenectomy. There were no
severe infections requiring hospitalization and no thrombotic complications.
● Two reports from 2015 and 2016 described outcomes in a consortium registry of patients
with a variety of congenital hemolytic anemias (Splenectomy in Congenital Hemolytic
Anemia [SICHA]) that included 61 children and adolescents with HS [174,175]. Procedures
were evenly divided between total and partial splenectomy; most were performed
laparoscopically. Hemoglobin increased in all of the children with HS (mean increase, 4.1
g/dL; greater increases with total than partial splenectomy), and transfusion dependence
in the group as a whole decreased from 22 to 4 percent [175].
● A 2001 series of 48 individuals with HS reported that those who had undergone
splenectomy had a mean hemoglobin of approximately 15 g/dL, and those who had not
undergone splenectomy had a mean hemoglobin of approximately 12 g/dL ( table 2)
[99].
Additional smaller series have reported similar findings, although some have observed more
concerning complications such as post-splenectomy sepsis [176-181]. (See 'Complications'
below.)
Pre-splenectomy considerations
Immunizations — For individuals considering splenectomy (total or partial), it is prudent

to ensure that all immunizations for encapsulated organisms have been administered with
sufficient time to develop an antibody response (typically approximately two weeks before the
surgery). Specific recommendations vary based on patient age and number of vaccine doses
previously received.
Details of specific vaccines are summarized in the tables for children ( table 3) and adults
( table 4) and discussed in separate topic reviews. (See "Prevention of infection in patients
with impaired splenic function", section on 'Vaccinations' and "Prevention of infection in
patients with impaired splenic function", section on 'Children' and "Elective (diagnostic or
therapeutic) splenectomy", section on 'Vaccinations'.)
Gallstones — For individuals with gallstones, it may be advantageous to perform

simultaneous cholecystectomy at the time of splenectomy. This decision takes into account the
size and symptoms of the stones as well as other operative factors. The use of cholecystectomy
in individuals with asymptomatic gallstones is controversial; patient values and preferences as
well as comorbidities and risks of complications such as cholangitis and acute biliary
pancreatitis in a patient with chronic hemolytic anemia and pigment gallstones should be
factored into this decision [182]. (See "Approach to the management of gallstones".)
Operative techniques — Splenectomy was traditionally performed as a total splenectomy via

laparotomy, which allows a search to be made for accessory splenic tissue, which may be
located at other sites within the abdomen. If not removed, an accessory spleen may grow and
result in the recurrence of symptomatic anemia [183].
However, laparoscopic splenectomy is increasingly used by surgeons with expertise in this

technique. There are no randomized trials comparing open versus laparoscopic splenectomy in
HS; however, observational studies in broader pediatric populations and case series have
observed that, when performed properly, laparoscopic splenectomy is associated with lower
complication rates and shorter hospital stays [184-189]. Laparoscopic splenectomy appears to
be equally effective in locating and removing an accessory spleen if present [187]. Thus,
laparoscopic splenectomy is used when there is appropriate institutional and surgical expertise
[118,190]. In rare cases with a very large spleen, it may be necessary to extend the incision. (See
"Elective (diagnostic or therapeutic) splenectomy", section on 'Surgical approach'.)
For younger children who cannot delay splenectomy until after five years of age, we suggest
partial splenectomy (also called subtotal or near-total splenectomy). There are no randomized
trials comparing partial splenectomy with total splenectomy in HS, and the decision between
total and partial splenectomy is made on a case-by-case basis. Compared with total
splenectomy, partial splenectomy is likely to be effective in reducing hemolysis while
maintaining splenic immune function, although it is probably less effective than total
splenectomy in reducing hemolysis [176,177,191-200].
Following partial splenectomy, the spleen eventually regrows and regains part or all of its
previous size, and a second (complete) splenectomy may be required. In many cases, this is
performed at a time when the patient is considerably older, with a reduced risk of sepsis. Some
individuals who undergo near-total splenectomy may have less regrowth of the splenic remnant
[194].
Partial/subtotal splenectomy should be accompanied by all of the precautions regarding

potential sepsis risk (eg, vaccinations, prophylactic antibiotics for at least a year postoperatively
and until residual splenic function can be determined) in case of secondary necrosis of the
splenic remnant [191].
Post-splenectomy course — In our experience, the typical post-splenectomy course includes

an increase in hemoglobin, a decrease in reticulocyte count, and a decrease in serum bilirubin
levels, all of which occur over the course of several days. Often, the hemoglobin and bilirubin
become normal or near normal, although RBC survival remains shorter than normal and the
reticulocyte count may remain mildly elevated.
In individuals with severe disease due to the common form of SPTA1-associated autosomal
recessive HS, the risk of life-threatening anemia and the need for regular transfusions is
eliminated, with the hemoglobin reaching normal and sometimes high normal levels with total
splenectomy; with partial splenectomy some degree of anemia may persist; adverse effects on
growth and development and pain due to splenomegaly will also be ameliorated.
This is consistent with observations published by other experts [118,136,165,201].
The likelihood of requiring cholecystectomy for gallstone disease may also be reduced, as noted
above; however, reducing the need for cholecystectomy should not be the sole indication for
splenectomy. (See 'Decision to pursue splenectomy' above.)
Patients with the most severe form of HS (near-fatal hydrops fetalis) with complete alpha-
spectrin or band 3 deficiency (due to biallelic null variants in SPTA1 or SLC4A1, respectively) do
not experience improvement with splenectomy. These patients have required in utero
transfusions to reach term delivery, or they were born prematurely and had RBC transfusion
support early in the neonatal period. They tend to have a characteristic reticulocytopenia even
with significant anemia. These patients can be managed with chronic transfusions and
chelation, similarly to thalassemia major patients, or with HSCT [35,81]. (See 'Beta spectrin or
alpha-spectrin deficiency due to SPTB or SPTA1 pathogenic variants' above and 'Transfusions'
above and 'Hematopoietic stem cell transplantation' below.)
Complications — Splenectomy has a number of known risks of which patients (or

parents/caregivers) should be aware [165].
General information about operative and postoperative risks is presented separately. (See
"Elective (diagnostic or therapeutic) splenectomy", section on 'Postoperative risks'.)
Evidence regarding postoperative risks specific to HS includes:
● Operative risks – Operative risks such as infection, bleeding, or injury to adjacent organs
such as the stomach or tail of the pancreas; these are relatively infrequent.
● Infections – Infections including overwhelming post-splenectomy infection (OPSI), from

encapsulated organisms (eg, Streptococcus pneumoniae, Neisseria meningitidis, H.
influenzae) that can no longer be removed by normal splenic clearance mechanisms, as
well as certain other microorganisms including plasmodia, Babesia, Bordetella, and
Capnocytophaga species (from animal bites) [165]. These risks are thought to be highest in
the first two to three years following splenectomy and in individuals undergoing
splenectomy before five to six years of age, but they also remain elevated for life [202].
• A 1973 review evaluated 850 patients, mostly infants and children, who had undergone
splenectomy for HS; 3.5 percent developed sepsis and 2.2 percent died of infection
[203].
• A 1995 review evaluated 226 patients with HS who underwent splenectomy up to 45

years earlier [204]. Four deaths from sepsis occurred 2, 18, 23, and 30 years after
splenectomy, and the estimated mortality from overwhelming sepsis was 0.73 per 1000
patient-years. The mortality rates for the 35 children who underwent splenectomy prior
to six years of age and for the 191 individuals who underwent splenectomy at an older
age were 1.12 and 0.66 per 1000 years, respectively, both of which were far higher than
those seen in the general population.
• A 1999 review of 264 children who underwent splenectomy at a single medical center
reported that 10 (3.8 percent) developed post-splenectomy sepsis within a mean period
of two years [205]. Nine of the 10 episodes occurred in patients whose surgery was
performed between the ages of zero and five years.
However, risks of sepsis are likely to have declined with improved options for preoperative
vaccinations and postoperative prophylactic penicillin. This was illustrated in a 1991 study
from the Danish National Patient Registry that demonstrated a dramatic reduction in
serious S. pneumoniae infections following pneumococcal vaccination [206]. Individuals
who did not receive appropriate pre-splenectomy vaccinations should have a thorough
review of their immunization history and should receive vaccinations as discussed
separately. (See "Prevention of infection in patients with impaired splenic function".)
● VTE – Venous thromboembolic (VTE) complications include thromboses of the deep veins,
pulmonary emboli, splenic or portal vein thrombosis, as well as thrombosis in other
unusual sites [207,208]. VTE events appear to be more common in individuals with HS who
undergo splenectomy than in those who do not, but the individuals who undergo
splenectomy may have had more severe underlying disease, making direct comparisons
difficult [137]. Thromboprophylaxis at the time of surgery should be based on standard
practices; there is no indication for extended thromboprophylaxis beyond the usual
duration [118]. This subject is discussed in detail separately:
• Children – (See "Venous thrombosis and thromboembolism (VTE) in children:

Treatment, prevention, and outcome", section on 'Approach to VTE prophylaxis'.)
• Adults – (See "Prevention of venous thromboembolic disease in adult nonorthopedic

surgical patients".)
● Arterial thrombosis – Arterial thrombotic events may also be increased relative to

individuals with HS who do not undergo splenectomy, with the same caveat that applies to
VTE (patients who undergo splenectomy may have more severe underlying disease)
[137,209].
● Pulmonary hypertension – It is not clear whether pulmonary artery hypertension (PAH) is

a complication of splenectomy in HS. A case report described an individual with HS who
underwent splenectomy at the age of 15 years and then developed PAH 32 years later
[210]. Retrospective studies have suggested that individuals who have undergone
splenectomy for HS and other hemolytic anemias are at greater risk of PAH than those
who have not undergone splenectomy; however, it is not clear whether the increased risk
is due to the underlying disorder, the splenectomy, or the combination [166,211-214]. In
some cases, affected individuals also had hypercoagulable states, potentially further
confounding a possible association [212,215]. If PAH occurs, it may take many years. In a
study that evaluated 26 children with HS at a median of 4.5 years after splenectomy, none
had evidence of PAH [216].
● Frequency of complications – In a 2009 administrative database review spanning the

years 1988 to 2004 that included 1657 children and adolescents <18 years with a diagnosis
of HS who underwent total splenectomy at an age range of 5 to 12 years, no adverse event
occurred in more than 1 percent of the cases during the hospitalization for surgery [217].
Hematopoietic stem cell transplantation — Allogeneic hematopoietic stem cell

transplantation (HSCT) is not used in common cases of HS due to an unfavorable risk-benefit
ratio; however, a case was reported in which an individual with both HS and chronic
myelogenous leukemia (CML) underwent allogeneic HSCT, which cured both disorders [218].
HSCT may be appropriate in the rare cases of autosomal recessive HS due to complete alpha-
spectrin or band 3 deficiency, presenting with near-fatal hydrops fetalis, requiring in utero
transfusions, or salvaged by premature delivery and early initiation of RBC transfusions; this
disease does not respond to splenectomy, and patients require either lifelong chronic
transfusions with iron chelation or HSCT [35]. (See 'Beta spectrin or alpha-spectrin deficiency
due to SPTB or SPTA1 pathogenic variants' above and 'Transfusions' above.)
Testing relatives; reproductive testing and counseling — If one child is born with HS, there
may be concern about HS in a sibling. Thus, if HS is diagnosed in a child, we obtain a full family
history and obtain a CBC, reticulocyte count, and examination of the peripheral blood smear on
each parent and sibling in order to determine whether the spherocytic gene variant is dominant
or recessive.
It is especially important to test a newborn sibling for HS, as well as newborns of affected
parents for HS (testing that may require additional confirmatory testing such as EMA binding,
osmotic gradient ektacytometry, or targeted sequencing for a known familial variant causing
HS), as this may be associated with severe degrees of hyperbilirubinemia and anemia during
the neonatal period. (See 'Confirmatory tests' above.)
Appropriate counseling can be performed once this information has been obtained. This may
be done by a clinician with expertise in hemolytic anemias or by a genetic counselor. It is
possible for an individual with no hemolysis, no spherocytes on the blood smear, and a normal
reticulocyte count to be a carrier of HS, which may be relevant in certain kindreds [118]. (See
"Genetic counseling: Family history interpretation and risk assessment".)
For individuals of childbearing age with HS, review of the familial gene variant and its mode of
transmission (autosomal dominant or recessive) may be useful for informing discussions of the
likelihood of HS in children. If the familial variant is known to act in an autosomal dominant
fashion, it is important to make this information clear in the prenatal record and to make the
information available to the pediatrician before delivery in order to stress the importance of
close monitoring for neonatal hyperbilirubinemia starting at the first day of life [119]. Some
individuals who had HS as a child and were treated with splenectomy may have forgotten about
the condition or may not realize the implications for their child.
SOCIETY GUIDELINE LINKS
Links to society and government-sponsored guidelines from selected countries and regions
around the world are provided separately. (See "Society guideline links: Anemia in adults".)
SUMMARY AND RECOMMENDATIONS
● Genetics and pathophysiology – Hereditary spherocytosis (HS) is a heterogeneous group

of disorders caused by variants in certain genes that encode proteins of the red blood cell
(RBC) membrane skeleton:
• Spectrin (SPTA1 and SPTB genes)

• Ankyrin (ANK1 gene)
• Band 3 (SLC4A1 gene)
• Protein 4.2 (EPB42 gene)
These abnormalities decrease the levels of proteins that link the RBC inner membrane
skeleton to the outer lipid bilayer ( figure 2), which in turn leads to membrane
vesiculation, spherocyte formation, and hemolysis. Approximately three-fourths of these
variants show autosomal dominant inheritance, 10 to 15 percent show autosomal
recessive inheritance, and the remainder are de novo variants, most frequently of ANK1,
causing new autosomal dominant disease. (See 'Pathophysiology' above.)
● Prevalence – HS is seen in all populations but appears to be especially common in people

of northern European ancestry, where it affects up to 1 in 2000 to 1 in 5000 (prevalence
0.02 to 0.05 percent). HS may account for as many as 1 percent of infants with neonatal
jaundice. (See 'Epidemiology' above.)
● Clinical findings – HS can present at any age and with any severity. The majority of
affected individuals have mild or moderate hemolytic anemia. Neonates with HS often
have jaundice and hyperbilirubinemia; the serum bilirubin level may not peak until several
days after birth, but it may increase rapidly, even on the first day of life. In older children
and adults, HS may present as an incidental finding of hemolytic anemia or spherocytes
on the blood smear ( picture 2), or the individual may be symptomatic from anemia,
splenomegaly, or pigment gallstones. Exacerbations of anemia may occur with parvovirus
infection, mononucleosis, or pregnancy. (See 'Clinical presentation' above.)
● Evaluation – All individuals with suspected HS based on a known family history and/or
clinical findings should have complete blood count (CBC) with reticulocyte count,
evaluation of RBC indices, review of the blood smear by an experienced individual, testing
for hemolysis, and direct antiglobulin testing (DAT; Coombs testing). In neonates or
infants, a mean corpuscular hemoglobin concentration (MCHC) ≥36 g/dL is highly
suggestive of HS. Spherocytes and reticulocytosis are less reliable indicators in infants but
are important in older children and adults. (See 'Initial testing' above.)
● Diagnostic confirmation – Several tests are available to confirm the diagnosis of HS (see
'Diagnosis' above):
• OF – Osmotic fragility is the traditional confirmatory test. (See 'Confirmatory tests'

above.)
• EMA – EMA (eosin-5-maleimide) binding is a widely available and sensitive test

requiring as little as 5 microL of blood. (See 'Confirmatory tests' above.)
• Ektacytometry – Osmotic gradient ektacytometry is very sensitive and the most

specific phenotypic test, especially in differentiating HS from other RBC membrane
disorders; it requires at least 0.3 mL of blood. (See 'Confirmatory tests' above.)
• NGS – Next generation DNA sequencing (NGS) is helpful if the patient has been
transfused and phenotypic testing of their RBCs is compromised with donor RBCs.
Sequencing panels for RBC membrane disorders or hereditary hemolytic anemias are
often used. NGS is also useful when deciding whether to pursue splenectomy and
making other treatment decisions. (See 'Specialized testing for selected cases
(including genetic testing)' above.)
● Differential diagnosis – The differential diagnosis of HS includes other hemolytic anemias

with spherocytes on the blood smear ( figure 5). Other inherited RBC membrane
disorders include hereditary elliptocytosis (HE), hereditary stomatocytosis or xerocytosis
syndromes (HSt or HX), and congenital dyserythropoietic anemia (CDA) type II. Other
possible diagnoses in neonates include neonatal alloimmune hemolytic anemia and
infantile pyknocytosis. Other possible diagnoses in children and adults include
autoimmune or drug-induced hemolytic anemias. (See 'Differential diagnosis' above.)
● Management – Treatment of HS is directed at minimizing complications of chronic

hemolysis and anemia. (See 'Management' above.)
• Monitoring and supportive care – Close monitoring is important for neonates, who
may require phototherapy for hyperbilirubinemia, and, in severe cases, exchange
transfusion. Even neonates with mild autosomal dominant HS may develop anemia
severe enough to require RBC transfusion two to three weeks after birth. If the
transfusion requirement persists after two to three months of age in these infants,
erythropoietin may be used to reduce transfusion requirements. For those with
moderate to severe hemolysis, we suggest folic acid supplementation (Grade 2C); a
typical dose is 1 mg/day. Higher folic acid doses are required during pregnancy, as
presented separately. (See 'Overview of treatment' above and "Preconception and
prenatal folic acid supplementation".)
• Transfusions – Blood transfusion is often required in infancy, even in mild autosomal

dominant HS. The transfusion requirement in the first months of life does not
necessarily predict a severe phenotype. Transfusions may be needed in older children
and adults in other settings (eg, aplastic or hemolytic crisis with infections, pregnancy).
Typical hemoglobin thresholds for transfusion depend on the age of the patient,
symptoms, and comorbidities. Transfusional iron overload may occur after transfusion
of >15 to 20 units of RBCs (>10 units in smaller children), and appropriate monitoring is
required, with chelation indicated in some cases. (See 'Transfusions' above.)
• Splenectomy – For children with HS whose disease remains transfusion-dependent or

who are severely symptomatic from anemia >1 year of age because of SPTA1-associated
autosomal recessive HS, we recommend a chronic transfusion program with chelation
until they are at least three years of age. Partial splenectomy can be considered at that
age (provided there is adequate surgical expertise) (Grade 2C). We suggest postponing
total splenectomy until >5 years of age, after the appropriate pre-splenectomy
immunizations are completed, to reduce the risk of sepsis. (Grade 2C). Some families
with children >5 years old may elect to have a total splenectomy rather than partial
splenectomy as the initial procedure. Observational data demonstrate a dramatic
reduction in transfusion requirements after splenectomy. The use of splenectomy in
individuals with moderate disease, typically autosomal dominant HS, is individualized
based on symptoms (discomfort from splenomegaly, distress from jaundice). In those
cases, partial splenectomy (provided there is adequate surgical expertise) may offer a
better balance of benefits versus long-term risks. (See 'Decision to pursue splenectomy'
above.)
• Pre-splenectomy considerations and splenectomy risks – For individuals

considering splenectomy, all immunizations for encapsulated organisms should be
administered with sufficient time to develop an antibody response. For individuals with
gallstones, it may be possible to perform simultaneous cholecystectomy at the time of
splenectomy. Patients should be aware of different operative techniques (partial versus
total splenectomy; open versus laparoscopic procedures) and potential complications,
which include potentially life-threatening sepsis, venous thromboembolism (VTE), and
possibly arterial thromboembolic events or pulmonary hypertension. It is important to
confirm that the patient does not have HSt, for which splenectomy is contraindicated
since it is neither safe nor effective in limiting hemolysis. (See 'Pre-splenectomy
considerations' above and 'Operative techniques' above and 'Complications' above and
"Elective (diagnostic or therapeutic) splenectomy", section on 'Postoperative risks'.)
• Relatives – Testing relatives, reproductive testing, and/or genetic counseling may be

useful. (See 'Testing relatives; reproductive testing and counseling' above.)
ACKNOWLEDGMENT
UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section

Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in
Hematology.
Use of UpToDate is subject to the Terms of Use.
REFERENCES
1. Lux SE 4th. Anatomy of the red cell membrane skeleton: unanswered questions. Blood
2016; 127:187.
2. Risinger M, Kalfa TA. Red cell membrane disorders: structure meets function. Blood 2020;
136:1250.
3. Narla J, Mohandas N. Red cell membrane disorders. Int J Lab Hematol 2017; 39 Suppl 1:47.
4. Eber S, Lux SE. Hereditary spherocytosis--defects in proteins that connect the membrane
skeleton to the lipid bilayer. Semin Hematol 2004; 41:118.
5. Jarolim P, Murray JL, Rubin HL, et al. Characterization of 13 novel band 3 gene defects in
hereditary spherocytosis with band 3 deficiency. Blood 1996; 88:4366.
6. Eber SW, Gonzalez JM, Lux ML, et al. Ankyrin-1 mutations are a major cause of dominant
and recessive hereditary spherocytosis. Nat Genet 1996; 13:214.
7. Dhermy D, Galand C, Bournier O, et al. Heterogenous band 3 deficiency in hereditary
spherocytosis related to different band 3 gene defects. Br J Haematol 1997; 98:32.
8. Falcón-Pérez JM, Dell'Angelica EC. The pallidin (Pldn) gene and the role of SNARE proteins in
melanosome biogenesis. Pigment Cell Res 2002; 15:82.
9. Moriyama K, Bonifacino JS. Pallidin is a component of a multi-protein complex involved in

the biogenesis of lysosome-related organelles. Traffic 2002; 3:666.
10. Peters LL, Shivdasani RA, Liu SC, et al. Anion exchanger 1 (band 3) is required to prevent
erythrocyte membrane surface loss but not to form the membrane skeleton. Cell 1996;
86:917.
11. Southgate CD, Chishti AH, Mitchell B, et al. Targeted disruption of the murine erythroid
band 3 gene results in spherocytosis and severe haemolytic anaemia despite a normal
membrane skeleton. Nat Genet 1996; 14:227.
12. Peters LL, Jindel HK, Gwynn B, et al. Mild spherocytosis and altered red cell ion transport in
protein 4. 2-null mice. J Clin Invest 1999; 103:1527.
13. Peters LL, Lux SE. Ankyrins: structure and function in normal cells and hereditary
spherocytes. Semin Hematol 1993; 30:85.
14. Inaba M, Yawata A, Koshino I, et al. Defective anion transport and marked spherocytosis
with membrane instability caused by hereditary total deficiency of red cell band 3 in cattle
due to a nonsense mutation. J Clin Invest 1996; 97:1804.
15. White RA, Sokolovsky IV, Britt MI, et al. Hematologic characterization and chromosomal
localization of the novel dominantly inherited mouse hemolytic anemia, neonatal anemia
(Nan). Blood Cells Mol Dis 2009; 43:141.
16. Heruth DP, Hawkins T, Logsdon DP, et al. Mutation in erythroid specific transcription factor
KLF1 causes Hereditary Spherocytosis in the Nan hemolytic anemia mouse model.
Genomics 2010; 96:303.
17. Nébor D, Graber JH, Ciciotte SL, et al. Mutant KLF1 in Adult Anemic Nan Mice Leads to
Profound Transcriptome Changes and Disordered Erythropoiesis. Sci Rep 2018; 8:12793.
18. Arnaud L, Saison C, Helias V, et al. A dominant mutation in the gene encoding the erythroid
transcription factor KLF1 causes a congenital dyserythropoietic anemia. Am J Hum Genet
2010; 87:721.
19. Fournier CM, Nicolas G, Gallagher PG, et al. Spectrin St Claude, a splicing mutation of the
human alpha-spectrin gene associated with severe poikilocytic anemia. Blood 1997;
89:4584.
20. Jarolim P, Wichterle H, Hanspal M, et al. Beta spectrin PRAGUE: a truncated beta spectrin
producing spectrin deficiency, defective spectrin heterodimer self-association and a
phenotype of spherocytic elliptocytosis. Br J Haematol 1995; 91:502.
21. Gibson SJ, Kalfa TA, DeStefano CB. Insane in the membrane: A case of hereditary
spherocytic pyropoikilocytosis. Am J Hematol 2022; 97:1384.
22. Mohandas N, Gallagher PG. Red cell membrane: past, present, and future. Blood 2008;
112:3939.
23. Andolfo I, Russo R, Gambale A, Iolascon A. New insights on hereditary erythrocyte
membrane defects. Haematologica 2016; 101:1284.
24. Mohandas N. Inherited hemolytic anemia: a possessive beginner's guide. Hematology Am
Soc Hematol Educ Program 2018; 2018:377.
25. Gallagher PG. Red cell membrane disorders. Hematology Am Soc Hematol Educ Program
2005; :13.
26. Randon J, Miraglia del Giudice E, Bozon M, et al. Frequent de novo mutations of the ANK1
gene mimic a recessive mode of transmission in hereditary spherocytosis: three new ANK1
variants: ankyrins Bari, Napoli II and Anzio. Br J Haematol 1997; 96:500.
27. del Giudice EM, Hayette S, Bozon M, et al. Ankyrin Napoli: a de novo deletional frameshift
mutation in exon 16 of ankyrin gene (ANK1) associated with spherocytosis. Br J Haematol
1996; 93:828.
28. Morlé L, Bozon M, Alloisio N, et al. Ankyrin Bugey: a de novo deletional frameshift variant in
exon 6 of the ankyrin gene associated with spherocytosis. Am J Hematol 1997; 54:242.
29. Miraglia del Giudice E, Francese M, Nobili B, et al. High frequency of de novo mutations in
ankyrin gene (ANK1) in children with hereditary spherocytosis. J Pediatr 1998; 132:117.
30. Miraglia del Giudice E, Lombardi C, Francese M, et al. Frequent de novo monoallelic
expression of beta-spectrin gene (SPTB) in children with hereditary spherocytosis and
isolated spectrin deficiency. Br J Haematol 1998; 101:251.
31. Miraglia del Giudice E, Nobili B, Francese M, et al. Clinical and molecular evaluation of non-
dominant hereditary spherocytosis. Br J Haematol 2001; 112:42.
32. Iolascon A, Miraglia del Giudice E, Perrotta S, et al. Hereditary spherocytosis: from clinical
to molecular defects. Haematologica 1998; 83:240.
33. Ribeiro ML, Alloisio N, Almeida H, et al. Severe hereditary spherocytosis and distal renal
tubular acidosis associated with the total absence of band 3. Blood 2000; 96:1602.
34. Kager L, Bruce LJ, Zeitlhofer P, et al. Band 3 nullVIENNA , a novel homozygous SLC4A1
p.Ser477X variant causing severe hemolytic anemia, dyserythropoiesis and complete distal
renal tubular acidosis. Pediatr Blood Cancer 2017; 64.
35. Chonat S, Risinger M, Sakthivel H, et al. The Spectrum of SPTA1-Associated Hereditary
Spherocytosis. Front Physiol 2019; 10:815.
36. Stenson PD, Mort M, Ball EV, et al. The Human Gene Mutation Database (HGMD®):
optimizing its use in a clinical diagnostic or research setting. Hum Genet 2020; 139:1197.
37. Stenson PD, Ball EV, Mort M, et al. Human Gene Mutation Database (HGMD): 2003 update.
Hum Mutat 2003; 21:577.
38. Gallagher PG. Hematologically important mutations: ankyrin variants in hereditary
spherocytosis. Blood Cells Mol Dis 2005; 35:345.
39. Luo Y, Li Z, Huang L, et al. Spectrum of Ankyrin Mutations in Hereditary Spherocytosis: A
Case Report and Review of the Literature. Acta Haematol 2018; 140:77.
40. Begtrup AH, Dagaonkar N, Pushkaran S, et al. Development of a comprehensive rapid next-
generation sequencing assay for the diagnosis of inherited hemolytic anemia. Blood 2013;
122:949.
41. Okamoto N, Wada Y, Nakamura Y, et al. Hereditary spherocytic anemia with deletion of the
short arm of chromosome 8. Am J Med Genet 1995; 58:225.
42. Jarolim P, Rubin HL, Brabec V, et al. Mutations of conserved arginines in the membrane
domain of erythroid band 3 lead to a decrease in membrane-associated band 3 and to the
phenotype of hereditary spherocytosis. Blood 1995; 85:634.
43. Lima PR, Gontijo JA, Lopes de Faria JB, et al. Band 3 Campinas: a novel splicing mutation in
the band 3 gene (AE1) associated with hereditary spherocytosis, hyperactivity of Na+/Li+
countertransport and an abnormal renal bicarbonate handling. Blood 1997; 90:2810.
44. Jenkins PB, Abou-Alfa GK, Dhermy D, et al. A nonsense mutation in the erythrocyte band 3
gene associated with decreased mRNA accumulation in a kindred with dominant hereditary
spherocytosis. J Clin Invest 1996; 97:373.
45. Miraglia del Giudice E, Vallier A, Maillet P, et al. Novel band 3 variants (bands 3 Foggia,
Napoli I and Napoli II) associated with hereditary spherocytosis and band 3 deficiency:
status of the D38A polymorphism within the EPB3 locus. Br J Haematol 1997; 96:70.
46. Maillet P, Vallier A, Reinhart WH, et al. Band 3 Chur: a variant associated with band 3-
deficient hereditary spherocytosis and substitution in a highly conserved position of
transmembrane segment 11. Br J Haematol 1995; 91:804.
47. Bianchi P, Zanella A, Alloisio N, et al. A variant of the EPB3 gene of the anti-Lepore type in
hereditary spherocytosis. Br J Haematol 1997; 98:283.
48. Tole S, Dhir P, Pugi J, et al. Genotype-phenotype correlation in children with hereditary
spherocytosis. Br J Haematol 2020; 191:486.
49. Alloisio N, Texier P, Vallier A, et al. Modulation of clinical expression and band 3 deficiency in
hereditary spherocytosis. Blood 1997; 90:414.
50. Alloisio N, Maillet P, Carré G, et al. Hereditary spherocytosis with band 3 deficiency.
Association with a nonsense mutation of the band 3 gene (allele Lyon), and aggravation by
a low-expression allele occurring in trans (allele Genas). Blood 1996; 88:1062.
51. Liu SC, Zhai S, Palek J, et al. Molecular defect of the band 3 protein in southeast Asian
ovalocytosis. N Engl J Med 1990; 323:1530.
52. Jarolim P, Palek J, Amato D, et al. Deletion in erythrocyte band 3 gene in malaria-resistant
Southeast Asian ovalocytosis. Proc Natl Acad Sci U S A 1991; 88:11022.
53. Bruce LJ, Cope DL, Jones GK, et al. Familial distal renal tubular acidosis is associated with
mutations in the red cell anion exchanger (Band 3, AE1) gene. J Clin Invest 1997; 100:1693.
54. Karet FE, Gainza FJ, Györy AZ, et al. Mutations in the chloride-bicarbonate exchanger gene
AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis.
Proc Natl Acad Sci U S A 1998; 95:6337.
55. Jarolim P, Shayakul C, Prabakaran D, et al. Autosomal dominant distal renal tubular acidosis
is associated in three families with heterozygosity for the R589H mutation in the AE1 (band
3) Cl-/HCO3- exchanger. J Biol Chem 1998; 273:6380.
56. Toye AM, Williamson RC, Khanfar M, et al. Band 3 Courcouronnes (Ser667Phe): a trafficking
mutant differentially rescued by wild-type band 3 and glycophorin A. Blood 2008; 111:5380.
57. Chu C, Woods N, Sawasdee N, et al. Band 3 Edmonton I, a novel mutant of the anion
exchanger 1 causing spherocytosis and distal renal tubular acidosis. Biochem J 2010;
426:379.
58. Chang YH, Shaw CF, Jian SH, et al. Compound mutations in human anion exchanger 1 are
associated with complete distal renal tubular acidosis and hereditary spherocytosis. Kidney
Int 2009; 76:774.
59. Kittanakom S, Cordat E, Reithmeier RA. Dominant-negative effect of Southeast Asian
ovalocytosis anion exchanger 1 in compound heterozygous distal renal tubular acidosis.
Biochem J 2008; 410:271.
60. Figueroa D. The Diego blood group system: a review. Immunohematology 2013; 29:73.
61. Rybicki AC, Qiu JJ, Musto S, et al. Human erythrocyte protein 4.2 deficiency associated with
hemolytic anemia and a homozygous 40glutamic acid-->lysine substitution in the
cytoplasmic domain of band 3 (band 3Montefiore). Blood 1993; 81:2155.
62. Barneaud-Rocca D, Borgese F, Guizouarn H. Dual transport properties of anion exchanger
1: the same transmembrane segment is involved in anion exchange and in a cation leak. J
Biol Chem 2011; 286:8909.
63. Bruce LJ, Robinson HC, Guizouarn H, et al. Monovalent cation leaks in human red cells
caused by single amino-acid substitutions in the transport domain of the band 3 chloride-
bicarbonate exchanger, AE1. Nat Genet 2005; 37:1258.
64. Bruce LJ. Hereditary stomatocytosis and cation-leaky red cells--recent developments. Blood
Cells Mol Dis 2009; 42:216.
65. Gallagher PG. Disorders of erythrocyte hydration. Blood 2017; 130:2699.
66. Iolascon A, De Falco L, Borgese F, et al. A novel erythroid anion exchange variant
(Gly796Arg) of hereditary stomatocytosis associated with dyserythropoiesis. Haematologica
2009; 94:1049.
67. Becker PS, Lux SE. Hereditary spherocytosis and related disorders. Clin Haematol 1985;
14:15.
68. Aggarwal A, Jamwal M, Sharma P, et al. Deciphering molecular heterogeneity of Indian

families with hereditary spherocytosis using targeted next-generation sequencing: First
South Asian study. Br J Haematol 2020; 188:784.

69. Hassoun H, Vassiliadis JN, Murray J, et al. Characterization of the underlying molecular
defect in hereditary spherocytosis associated with spectrin deficiency. Blood 1997; 90:398.
70. Becker PS, Tse WT, Lux SE, Forget BG. Beta spectrin kissimmee: a spectrin variant
associated with autosomal dominant hereditary spherocytosis and defective binding to
protein 4.1. J Clin Invest 1993; 92:612.
71. Dhermy D, Galand C, Bournier O, et al. Hereditary spherocytosis with spectrin deficiency
related to null mutations of the beta-spectrin gene. Blood Cells Mol Dis 1998; 24:251.
72. Garbarz M, Galand C, Bibas D, et al. A 5' splice region G-->C mutation in exon 3 of the
human beta-spectrin gene leads to decreased levels of beta-spectrin mRNA and is
responsible for dominant hereditary spherocytosis (spectrin Guemene-Penfao). Br J
Haematol 1998; 100:90.
73. Hassoun H, Vassiliadis JN, Murray J, et al. Molecular basis of spectrin deficiency in beta
spectrin Durham. A deletion within beta spectrin adjacent to the ankyrin-binding site
precludes spectrin attachment to the membrane in hereditary spherocytosis. J Clin Invest
1995; 96:2623.
74. Hassoun H, Vassiliadis JN, Murray J, et al. Hereditary spherocytosis with spectrin deficiency
due to an unstable truncated beta spectrin. Blood 1996; 87:2538.
75. Maciag M, Płochocka D, Adamowicz-Salach A, Burzyńska B. Novel beta-spectrin mutations
in hereditary spherocytosis associated with decreased levels of mRNA. Br J Haematol 2009;
146:326.
76. Fermo E, Vercellati C, Marcello AP, et al. Targeted Next Generation Sequencing and
Diagnosis of Congenital Hemolytic Anemias: A Three Years Experience Monocentric Study.
Front Physiol 2021; 12:684569.
77. Tse WT, Gallagher PG, Jenkins PB, et al. Amino-acid substitution in alpha-spectrin commonly
coinherited with nondominant hereditary spherocytosis. Am J Hematol 1997; 54:233.
78. Bogardus H, Schulz VP, Maksimova Y, et al. Severe nondominant hereditary spherocytosis
due to uniparental isodisomy at the SPTA1 locus. Haematologica 2014; 99:e168.
79. Wichterle H, Hanspal M, Palek J, Jarolim P. Combination of two mutant alpha spectrin alleles
underlies a severe spherocytic hemolytic anemia. J Clin Invest 1996; 98:2300.
80. Gallagher PG, Maksimova Y, Lezon-Geyda K, et al. Aberrant splicing contributes to severe α-
spectrin-linked congenital hemolytic anemia. J Clin Invest 2019; 129:2878.
81. Kalfa TA. Diagnosis and clinical management of red cell membrane disorders. Hematology
Am Soc Hematol Educ Program 2021; 2021:331.
82. Yawata Y, Yawata A, Kanzaki A, et al. Electron microscopic evidence of impaired

intramembrane particles and instability of the cytoskeletal network in band 4.2 deficiency
in human red cells. Cell Motil Cytoskeleton 1996; 33:95.
83. Perrotta S, Iolascon A, Polito R, et al. 4.2 Nippon mutation in a non-Japanese patient with
hereditary spherocytosis. Haematologica 1999; 84:660.
84. Hammill AM, Risinger MA, Joiner CH, et al. Compound heterozygosity for two novel
mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient.
Br J Haematol 2011; 152:780.
85. Bouhassira EE, Schwartz RS, Yawata Y, et al. An alanine-to-threonine substitution in protein
4.2 cDNA is associated with a Japanese form of hereditary hemolytic anemia (protein
4.2NIPPON). Blood 1992; 79:1846.
86. Kalfa TA, Begtrup AH. EPB42-Related Hereditary Spherocytosis. In: GeneReviews, Adam MP,
Mirzaa GM, Pagon RA, Wallace SE, Bean LJH (Eds), University of Washington, Seattle, Seattle
(WA) 1993.
87. Takaoka Y, Ideguchi H, Matsuda M, et al. A novel mutation in the erythrocyte protein 4.2
gene of Japanese patients with hereditary spherocytosis (protein 4.2 Fukuoka). Br J
Haematol 1994; 88:527.
88. Kanzaki A, Yasunaga M, Okamoto N, et al. Band 4.2 Shiga: 317 CGC-->TGC in compound
heterozygotes with 142 GCT-->ACT results in band 4.2 deficiency and microspherocytosis.
Br J Haematol 1995; 91:333.
89. Matsuda M, Hatano N, Ideguchi H, et al. A novel mutation causing an aberrant splicing in
the protein 4.2 gene associated with hereditary spherocytosis (protein 4.2Notame). Hum
Mol Genet 1995; 4:1187.
90. van den Akker E, Satchwell TJ, Pellegrin S, et al. Investigating the key membrane protein
changes during in vitro erythropoiesis of protein 4.2 (-) cells (mutations Chartres 1 and 2).
Haematologica 2010; 95:1278.
91. Jarolim P, Palek J, Rubin HL, et al. Band 3 Tuscaloosa: Pro327----Arg327 substitution in the
cytoplasmic domain of erythrocyte band 3 protein associated with spherocytic hemolytic
anemia and partial deficiency of protein 4.2. Blood 1992; 80:523.
92. Inoue T, Kanzaki A, Kaku M, et al. Homozygous missense mutation (band 3 Fukuoka:
G130R): a mild form of hereditary spherocytosis with near-normal band 3 content and
minimal changes of membrane ultrastructure despite moderate protein 4.2 deficiency. Br J
Haematol 1998; 102:932.
93. Kanzaki A, Hayette S, Morlé L, et al. Total absence of protein 4.2 and partial deficiency of
band 3 in hereditary spherocytosis. Br J Haematol 1997; 99:522.
94. Bustos SP, Reithmeier RA. Structure and stability of hereditary spherocytosis mutants of the
cytosolic domain of the erythrocyte anion exchanger 1 protein. Biochemistry 2006; 45:1026.
95. Salomao M, Chen K, Villalobos J, et al. Hereditary spherocytosis and hereditary
elliptocytosis: aberrant protein sorting during erythroblast enucleation. Blood 2010;
116:267.
96. An X, Mohandas N. Disorders of red cell membrane. Br J Haematol 2008; 141:367.

97. Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet 2008; 372:1411.
98. Bolton-Maggs PH, Stevens RF, Dodd NJ, et al. Guidelines for the diagnosis and
management of hereditary spherocytosis. Br J Haematol 2004; 126:455.
99. Da Costa L, Mohandas N, Sorette M, et al. Temporal differences in membrane loss lead to
distinct reticulocyte features in hereditary spherocytosis and in immune hemolytic anemia.
Blood 2001; 98:2894.
100. Lux SE, Palek J. Disorders of the red cell membrane. In: Blood. Principles and Practice of He
matology, Handin RI, Lux SE, Stossel TP (Eds), Lippincott, Philadelphia 1995. p.1701.
101. De Franceschi L, Olivieri O, Miraglia del Giudice E, et al. Membrane cation and anion
transport activities in erythrocytes of hereditary spherocytosis: effects of different
membrane protein defects. Am J Hematol 1997; 55:121.
102. Joiner CH, Franco RS, Jiang M, et al. Increased cation permeability in mutant mouse red
blood cells with defective membrane skeletons. Blood 1995; 86:4307.
103. Safeukui I, Buffet PA, Deplaine G, et al. Quantitative assessment of sensing and
sequestration of spherocytic erythrocytes by the human spleen. Blood 2012; 120:424.
104. Klei TRL, Dalimot J, Nota B, et al. Hemolysis in the spleen drives erythrocyte turnover. Blood
2020; 136:1579.
105. Agre P, Orringer EP, Bennett V. Deficient red-cell spectrin in severe, recessively inherited
spherocytosis. N Engl J Med 1982; 306:1155.
106. Schrier SL. What does the spleen see? Blood 2012; 120:242.
107. Li H, Lu L, Li X, et al. Mechanics of diseased red blood cells in human spleen and
consequences for hereditary blood disorders. Proc Natl Acad Sci U S A 2018; 115:9574.
108. Ingrosso D, D'Angelo S, Perrotta S, et al. Cytoskeletal behaviour in spectrin and in band 3
deficient spherocytic red cells: evidence for differentiated splenic conditioning role. Br J
Haematol 1996; 93:38.
109. van Zwieten R, van Oirschot BA, Veldthuis M, et al. Partial pyruvate kinase deficiency
aggravates the phenotypic expression of band 3 deficiency in a family with hereditary
spherocytosis. Am J Hematol 2015; 90:E35.
110. Andres O, Loewecke F, Morbach H, et al. Hereditary spherocytosis is associated with
decreased pyruvate kinase activity due to impaired structural integrity of the red blood cell
membrane. Br J Haematol 2019; 187:386.
111. Eber SW, Pekrun A, Neufeldt A, Schröter W. Prevalence of increased osmotic fragility of
erythrocytes in German blood donors: screening using a modified glycerol lysis test. Ann
Hematol 1992; 64:88.
112. Saada V, Cynober T, Brossard Y, et al. Incidence of hereditary spherocytosis in a population
of jaundiced neonates. Pediatr Hematol Oncol 2006; 23:387.
113. van Vuren A, van der Zwaag B, Huisjes R, et al. The Complexity of Genotype-Phenotype
Correlations in Hereditary Spherocytosis: A Cohort of 95 Patients: Genotype-Phenotype
Correlation in Hereditary Spherocytosis. Hemasphere 2019; 3:e276.
114. Whitfield CF, Follweiler JB, Lopresti-Morrow L, Miller BA. Deficiency of alpha-spectrin
synthesis in burst-forming units-erythroid in lethal hereditary spherocytosis. Blood 1991;
78:3043.
115. Friedman EW, Williams JC, Van Hook L. Hereditary spherocytosis in the elderly. Am J Med
1988; 84:513.
116. Eber SW, Armbrust R, Schröter W. Variable clinical severity of hereditary spherocytosis:
relation to erythrocytic spectrin concentration, osmotic fragility, and autohemolysis. J
Pediatr 1990; 117:409.
117. del Giudice EM, Perrotta S, Nobili B, et al. Coinheritance of Gilbert syndrome increases the
risk for developing gallstones in patients with hereditary spherocytosis. Blood 1999;
94:2259.
118. Bolton-Maggs PH, Langer JC, Iolascon A, et al. Guidelines for the diagnosis and
management of hereditary spherocytosis--2011 update. Br J Haematol 2012; 156:37.
119. Christensen RD, Yaish HM, Gallagher PG. A pediatrician's practical guide to diagnosing and
treating hereditary spherocytosis in neonates. Pediatrics 2015; 135:1107.
120. Delhommeau F, Cynober T, Schischmanoff PO, et al. Natural history of hereditary
spherocytosis during the first year of life. Blood 2000; 95:393.
121. Schröter W, Kahsnitz E. Diagnosis of hereditary spherocytosis in newborn infants. J Pediatr
1983; 103:460.
122. Tchernia G, Delhommeau F, Perrotta S, et al. Recombinant erythropoietin therapy as an

alternative to blood transfusions in infants with hereditary spherocytosis. Hematol J 2000;
1:146.
123. Elbadry MI, Khaled SAA, Ahmed NM, et al. Acute human parvovirus B19 infection triggers
immune-mediated transient bone marrow failure syndrome, extreme direct
hyperbilirubinaemia and acute hepatitis in patients with hereditary haemolytic anaemias:
multicentre prospective pathophysiological study. Br J Haematol 2021; 193:827.
124. Taher AT, Iolascon A, Matar CF, et al. Recommendations for Pregnancy in Rare Inherited
Anemias. Hemasphere 2020; 4:e446.
125. Pitkin RM. Folate and neural tube defects. Am J Clin Nutr 2007; 85:285S.
126. Fisher AL, Sangkhae V, Balušíková K, et al. Iron-dependent apoptosis causes embryotoxicity
in inflamed and obese pregnancy. Nat Commun 2021; 12:4026.
127. Bastion Y, Coiffier B, Felman P, et al. Massive mediastinal extramedullary hematopoiesis in
hereditary spherocytosis: a case report. Am J Hematol 1990; 35:263.
128. Smith J, Rahilly M, Davidson K. Extramedullary haematopoiesis secondary to hereditary
spherocytosis. Br J Haematol 2011; 154:543.
129. Tole S, Amid A, Baker J, et al. Mild Hereditary Spherocytosis without Accompanying
Hereditary Haemochromatosis: An Unrecognised Cause of Iron Overload. Acta Haematol
2019; 141:256.
130. Rabhi S, Benjelloune H, Meziane M, et al. Hereditary spherocytosis with leg ulcers healing
after splenectomy. South Med J 2011; 104:150.
131. Prabhakaran K, Jacobs BL, Smaldone MC, Franks ME. Stuttering priapism associated with
hereditary spherocytosis. Can J Urol 2007; 14:3702.
132. Christensen RD, Henry E. Hereditary spherocytosis in neonates with hyperbilirubinemia.

Pediatrics 2010; 125:120.
133. MACKINNEY AA Jr. HEREDITARY SPHEROCYTOSIS; CLINICAL FAMILY STUDIES. Arch Intern
Med 1965; 116:257.
134. BATES GC, BROWN CH. Incidence of gallbladder disease in chronic hemolytic anemia
(spherocytosis). Gastroenterology 1952; 21:104.
135. Ruparel RK, Bogert JN, Moir CR, et al. Synchronous splenectomy during cholecystectomy
for hereditary spherocytosis: is it really necessary? J Pediatr Surg 2014; 49:433.
136. Schilling RF. Risks and benefits of splenectomy versus no splenectomy for hereditary
spherocytosis--a personal view. Br J Haematol 2009; 145:728.
137. Schilling RF, Gangnon RE, Traver MI. Delayed adverse vascular events after splenectomy in
hereditary spherocytosis. J Thromb Haemost 2008; 6:1289.
138. Segel GB, Lichtman MA. Direct antiglobulin ("Coombs") test-negative autoimmune
hemolytic anemia: a review. Blood Cells Mol Dis 2014; 52:152.
139. Kalfa TA. Warm antibody autoimmune hemolytic anemia. Hematology Am Soc Hematol
Educ Program 2016; 2016:690.
140. Voulgaridou A, Kalfa TA. Autoimmune Hemolytic Anemia in the Pediatric Setting. J Clin Med
2021; 10.
141. King MJ, Garçon L, Hoyer JD, et al. ICSH guidelines for the laboratory diagnosis of
nonimmune hereditary red cell membrane disorders. Int J Lab Hematol 2015; 37:304.
142. Coetzer TL, Lawler J, Liu SC, et al. Partial ankyrin and spectrin deficiency in severe, atypical
hereditary spherocytosis. N Engl J Med 1988; 318:230.
143. Palek J, Jarolim P. Clinical expression and laboratory detection of red blood cell membrane
protein mutations. Semin Hematol 1993; 30:249.
144. Michaels LA, Cohen AR, Zhao H, et al. Screening for hereditary spherocytosis by use of
automated erythrocyte indexes. J Pediatr 1997; 130:957.
145. Ciepiela O, Kotuła I, Górska E, et al. Delay in the measurement of eosin-5′-maleimide (EMA)
binding does not affect the test result for the diagnosis of hereditary spherocytosis. Clin
Chem Lab Med 2013; 51:817.
146. Hoffman R, Benz EJ Jr, Silberstein LE, et al. Red blood cell membrane disorders. In: Hematol
ogy: Basic Principles and Practice, 7th ed, Hoffman R, Benz EJ Jr, Silberstein LE, et al (Eds), El
sevier, Philadelphia 2018. p.632.
147. Bianchi P, Fermo E, Vercellati C, et al. Diagnostic power of laboratory tests for hereditary
spherocytosis: a comparison study in 150 patients grouped according to molecular and
clinical characteristics. Haematologica 2012; 97:516.
148. King MJ, Behrens J, Rogers C, et al. Rapid flow cytometric test for the diagnosis of
membrane cytoskeleton-associated haemolytic anaemia. Br J Haematol 2000; 111:924.
149. Crisp RL, Solari L, Gammella D, et al. Use of capillary blood to diagnose hereditary
spherocytosis. Pediatr Blood Cancer 2012; 59:1299.
150. Christensen RD, Agarwal AM, Nussenzveig RH, et al. Evaluating eosin-5-maleimide binding
as a diagnostic test for hereditary spherocytosis in newborn infants. J Perinatol 2015;
35:357.
151. Cheli E, Roze J, Garrot T, et al. Usefulness of the EMA flow cytometric test in the diagnosis of
hereditary spherocytosis post-transfusion. Br J Haematol 2017; 178:180.
152. Kar R, Mishra P, Pati HP. Evaluation of eosin-5-maleimide flow cytometric test in diagnosis
of hereditary spherocytosis. Int J Lab Hematol 2010; 32:8.
153. Stoya G, Gruhn B, Vogelsang H, et al. Flow cytometry as a diagnostic tool for hereditary
spherocytosis. Acta Haematol 2006; 116:186.
154. Crisp RL, Solari L, Vota D, et al. A prospective study to assess the predictive value for
hereditary spherocytosis using five laboratory tests (cryohemolysis test, eosin-5'-maleimide
flow cytometry, osmotic fragility test, autohemolysis test, and SDS-PAGE) on 50 hereditary
spherocytosis families in Argentina. Ann Hematol 2011; 90:625.
155. Ciepiela O, Nowak M, Wrońska M, et al. Eosin-5'-maleimide binding test-Do we use
appropriate reference values to detect hereditary spherocytosis in neonates? Int J Lab
Hematol 2019; 41:e57.
156. Da Costa L, Suner L, Galimand J, et al. Diagnostic tool for red blood cell membrane
disorders: Assessment of a new generation ektacytometer. Blood Cells Mol Dis 2016; 56:9.
157. Cynober T, Mohandas N, Tchernia G. Red cell abnormalities in hereditary spherocytosis:
relevance to diagnosis and understanding of the variable expression of clinical severity. J
Lab Clin Med 1996; 128:259.
158. Bessis M, Mohandas N, Feo C. Automated ektacytometry: a new method of measuring red
cell deformability and red cell indices. Blood Cells 1980; 6:315.
159. Mohandas N, Clark MR, Jacobs MS, Shohet SB. Analysis of factors regulating erythrocyte
deformability. J Clin Invest 1980; 66:563.
160. Zaninoni A, Fermo E, Vercellati C, et al. Use of Laser Assisted Optical Rotational Cell
Analyzer (LoRRca MaxSis) in the Diagnosis of RBC Membrane Disorders, Enzyme Defects,
and Congenital Dyserythropoietic Anemias: A Monocentric Study on 202 Patients. Front
Physiol 2018; 9:451.
161. Bucx MJ, Breed WP, Hoffmann JJ. Comparison of acidified glycerol lysis test, Pink test and
osmotic fragility test in hereditary spherocytosis: effect of incubation. Eur J Haematol 1988;
40:227.
162. Judkiewicz L, Szczepanek A, Bugała I, Bartosz G. Modified end-point glycerol hemolysis
assay as a screening test for hereditary spherocytosis that requires no venipuncture. Am J
Hematol 1987; 26:89.
163. Streichman S, Gescheidt Y. Cryohemolysis for the detection of hereditary spherocytosis:
correlation studies with osmotic fragility and autohemolysis. Am J Hematol 1998; 58:206.
164. Romero RR, Poo JL, Robles JA, et al. Usefulness of cryohemolysis test in the diagnosis of
hereditary spherocytosis. Arch Med Res 1997; 28:247.
165. Iolascon A, Andolfo I, Barcellini W, et al. Recommendations regarding splenectomy in

hereditary hemolytic anemias. Haematologica 2017; 102:1304.
166. Stewart GW, Amess JA, Eber SW, et al. Thrombo-embolic disease after splenectomy for
hereditary stomatocytosis. Br J Haematol 1996; 93:303.
167. Picard V, Guitton C, Thuret I, et al. Clinical and biological features in PIEZO1-hereditary
xerocytosis and Gardos channelopathy: a retrospective series of 126 patients.
Haematologica 2019; 104:1554.
168. El Nabouch M, Rakotoharinandrasana I, Ndayikeza A, et al. Infantile pyknocytosis, a rare

cause of hemolytic anemia in newborns: report of two cases in twin girls and literature
overview. Clin Case Rep 2015; 3:535.
169. Anselstetter V, Horstmann HJ, Heimpel H. Congenital dyserythropoietic anaemia, types I
and II: aberrant pattern of erythrocyte membrane proteins in CDA II, as revealed by two-
dimensional polyacrylamide gel electrophoresis. Br J Haematol 1977; 35:209.
170. Rothman JA, Stevens JL, Gray FL, Kalfa TA. How I approach hereditary hemolytic anemia and
splenectomy. Pediatr Blood Cancer 2020; 67:e28337.
171. Manno CS, Cohen AR. Splenectomy in mild hereditary spherocytosis: is it worth the risk?
Am J Pediatr Hematol Oncol 1989; 11:300.
172. Kimura F, Ito H, Shimizu H, et al. Partial splenic embolization for the treatment of
hereditary spherocytosis. AJR Am J Roentgenol 2003; 181:1021.
173. Pincez T, Guitton C, Gauthier F, et al. Long-term follow-up of subtotal splenectomy for
hereditary spherocytosis: a single-center study. Blood 2016; 127:1616.
174. Rice HE, Englum BR, Rothman J, et al. Clinical outcomes of splenectomy in children: report
of the splenectomy in congenital hemolytic anemia registry. Am J Hematol 2015; 90:187.
175. Englum BR, Rothman J, Leonard S, et al. Hematologic outcomes after total splenectomy
and partial splenectomy for congenital hemolytic anemia. J Pediatr Surg 2016; 51:122.
176. Buesing KL, Tracy ET, Kiernan C, et al. Partial splenectomy for hereditary spherocytosis: a
multi-institutional review. J Pediatr Surg 2011; 46:178.
177. Slater BJ, Chan FP, Davis K, Dutta S. Institutional experience with laparoscopic partial
splenectomy for hereditary spherocytosis. J Pediatr Surg 2010; 45:1682.
178. Rosman CWK, Broens PMA, Trzpis M, Tamminga RYJ. A long-term follow-up study of
subtotal splenectomy in children with hereditary spherocytosis. Pediatr Blood Cancer 2017;
64.
179. Pugi J, Carcao M, Drury LJ, Langer JC. Results after laparoscopic partial splenectomy for
children with hereditary spherocytosis: Are outcomes influenced by genetic mutation? J
Pediatr Surg 2018; 53:973.

180. Das A, Bansal D, Das R, et al. Hereditary spherocytosis in children: profile and post-
splenectomy outcome. Indian Pediatr 2014; 51:139.
181. Oliveira MC, Fernandes RA, Rodrigues CL, et al. Clinical course of 63 children with
hereditary spherocytosis: a retrospective study. Rev Bras Hematol Hemoter 2012; 34:9.
182. Lee BJH, Yap QV, Low JK, et al. Cholecystectomy for asymptomatic gallstones: Markov
decision tree analysis. World J Clin Cases 2022; 10:10399.
183. Mackenzie AE, Elliot DH, Eastcott HH, et al. Relapse in hereditary spherocytosis with proven
splenunculus. Lancet 1962; 1:1102.
184. Curran TJ, Foley MI, Swanstrom LL, Campbell TJ. Laparoscopy improves outcomes for
pediatric splenectomy. J Pediatr Surg 1998; 33:1498.
185. Rescorla FJ, Breitfeld PP, West KW, et al. A case controlled comparison of open and
laparoscopic splenectomy in children. Surgery 1998; 124:670.
186. Tanoue K, Okita K, Akahoshi T, et al. Laparoscopic splenectomy for hematologic diseases.
Surgery 2002; 131:S318.
187. Wood JH, Partrick DA, Hays T, et al. Contemporary pediatric splenectomy: continuing
controversies. Pediatr Surg Int 2011; 27:1165.
188. Rescorla FJ, West KW, Engum SA, Grosfeld JL. Laparoscopic splenic procedures in children:
experience in 231 children. Ann Surg 2007; 246:683.
189. Delaitre B, Champault G, Barrat C, et al. [Laparoscopic splenectomy for hematologic
diseases. Study of 275 cases. French Society of Laparoscopic Surgery]. Ann Chir 2000;
125:522.
190. Shakya VC, Byanjankar B, Pandit R, et al. Challenges and Results of Laparoscopic
Splenectomy for Hematological Diseases in a Developing Country. Minim Invasive Surg
2018; 2018:4256570.
191. Bader-Meunier B, Gauthier F, Archambaud F, et al. Long-term evaluation of the beneficial
effect of subtotal splenectomy for management of hereditary spherocytosis. Blood 2001;
97:399.
192. Tchernia G, Bader-Meunier B, Berterottiere P, et al. Effectiveness of partial splenectomy in
hereditary spherocytosis. Curr Opin Hematol 1997; 4:136.
193. Stoehr GA, Stauffer UG, Eber SW. Near-total splenectomy: a new technique for the
management of hereditary spherocytosis. Ann Surg 2005; 241:40.
194. Stoehr GA, Sobh JN, Luecken J, et al. Near-total splenectomy for hereditary spherocytosis:
clinical prospects in relation to disease severity. Br J Haematol 2006; 132:791.
195. Dutta S, Price VE, Blanchette V, Langer JC. A laparoscopic approach to partial splenectomy
for children with hereditary spherocytosis. Surg Endosc 2006; 20:1719.
196. Tracy ET, Rice HE. Partial splenectomy for hereditary spherocytosis. Pediatr Clin North Am
2008; 55:503.
197. Morinis J, Dutta S, Blanchette V, et al. Laparoscopic partial vs total splenectomy in children
with hereditary spherocytosis. J Pediatr Surg 2008; 43:1649.
198. Vasilescu C, Stanciulea O, Tudor S. Laparoscopic versus robotic subtotal splenectomy in
hereditary spherocytosis. Potential advantages and limits of an expensive approach. Surg
Endosc 2012; 26:2802.
199. Vasilescu C, Stanciulea O, Tudor S, et al. Laparoscopic subtotal splenectomy in hereditary
spherocytosis : to preserve the upper or the lower pole of the spleen? Surg Endosc 2006;
20:748.
200. Liu G, Fan Y. Feasibility and Safety of Laparoscopic Partial Splenectomy: A Systematic
Review. World J Surg 2019; 43:1505.
201. Agre P, Asimos A, Casella JF, McMillan C. Inheritance pattern and clinical response to
splenectomy as a reflection of erythrocyte spectrin deficiency in hereditary spherocytosis.
N Engl J Med 1986; 315:1579.
202. Luu S, Spelman D, Woolley IJ. Post-splenectomy sepsis: preventative strategies, challenges,
and solutions. Infect Drug Resist 2019; 12:2839.
203. Singer DB. Postsplenectomy sepsis. Perspect Pediatr Pathol 1973; 1:285.
204. Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis.
Ann Intern Med 1995; 122:187.
205. Jugenburg M, Haddock G, Freedman MH, et al. The morbidity and mortality of pediatric
splenectomy: does prophylaxis make a difference? J Pediatr Surg 1999; 34:1064.
206. Konradsen HB, Henrichsen J. Pneumococcal infections in splenectomized children are
preventable. Acta Paediatr Scand 1991; 80:423.
207. Davidsen C, Larsen TH, Gerdts E, Lønnebakken MT. Giant right ventricular outflow tract
thrombus in hereditary spherocytosis: a case report. Thromb J 2016; 14:9.
208. Perkins LA, Jones SF, Bhargava RS. Dural venous thrombosis following splenectomy in a
patient with hereditary spherocytosis. South Med J 2009; 102:542.
209. Schilling RF. Spherocytosis, splenectomy, strokes, and heat attacks. Lancet 1997; 350:1677.
210. Smedema JP, Louw VJ. Pulmonary arterial hypertension after splenectomy for hereditary
spherocytosis. Cardiovasc J Afr 2007; 18:84.
211. Verresen D, De Backer W, Van Meerbeeck J, et al. Spherocytosis and pulmonary

hypertension coincidental occurrence or causal relationship? Eur Respir J 1991; 4:629.
212. Hayag-Barin JE, Smith RE, Tucker FC Jr. Hereditary spherocytosis, thrombocytosis, and
chronic pulmonary emboli: a case report and review of the literature. Am J Hematol 1998;
57:82.
213. Tso SC, Chan TK, Todd D. Venous thrombosis in haemoglobin H disease after splenectomy.
Aust N Z J Med 1982; 12:635.
214. Robinette CD, Fraumeni JF Jr. Splenectomy and subsequent mortality in veterans of the
1939-45 war. Lancet 1977; 2:127.
215. Bhargava K, Chandra N, Omar AK, Mathur A. Protein C deficiency leading to pulmonary
thromboembolism in a patient with hereditary spherocytosis. Indian Heart J 2006; 58:444.
216. Das A, Bansal D, Ahluwalia J, et al. Risk factors for thromboembolism and pulmonary artery
hypertension following splenectomy in children with hereditary spherocytosis. Pediatr
Blood Cancer 2014; 61:29.
217. Abdullah F, Zhang Y, Camp M, et al. Splenectomy in hereditary spherocytosis: Review of
1,657 patients and application of the pediatric quality indicators. Pediatr Blood Cancer
2009; 52:834.
218. Zhang XH, Fu HX, Xu LP, et al. Allo-hematopoietic stem cell transplantation is a potential
treatment for a patient with a combined disorder of hereditary spherocytosis. Chin Med J
(Engl) 2012; 125:947.
Topic 7079 Version 46.0
GRAPHICS
RBC membrane protein abnormalities and sites of the responsible gene

mutations in hereditary spherocytosis, hereditary elliptocytosis, and hereditar
pyropoikilocytosis
(A) The domain structure of these proteins is shown, with positions of known mutations causing HS and
HE/HPP indicated beneath each protein.
(B) The structure of the spectrin tetramer is shown, illustrating the triple helical coiled-coil repeats of the
spectrin peptides, the head-to-head spectrin self-association sites, and the nucleation sites that initiate
the side-to-side interaction between alpha- and beta-spectrin chains.
RBC: red blood cell; HS: hereditary spherocytosis; HE: hereditary elliptocytosis; HPP: hereditary
pyropoikilocytosis.
Reproduced with permission from: Tse WT, Lux SE. Red blood cell membrane disorders. Br J Haematol 1999; 104:2. Copyright 1999
Blackwell Science.
Graphic 55451 Version 5.0
Multiprotein complexes in the red blood cell membrane
Schematic representation of two types of multiprotein complexes in the red blood cell membrane.
(Left) Band 3-based macromolecular complex (referred to as Ankyrin complex in the image). This protein
complex attaches to spectrin near the center of the tetramer (dimer-dimer interaction site). Tetrameric
band 3 is bound to ankyrin, which is bound to spectrin. The membrane skeletal protein 4.2 has binding
sites for band 3 and for ankyrin. Transmembrane glycoproteins GPA, Rh, and RhAG bind to band 3, and
CD47 and LW associate with Rh/RhAG. The two cytoplasmic domains of band 3 contain binding sites for
soluble proteins, the short C-terminal domain for CA II, the large N-terminal domain for
deoxyhemoglobin, glycolytic enzymes, aldolase, PFK, and GAPDH.
(Right) Protein 4.1R-based macromolecular complex. This protein complex forms at membrane skeletal
junctions. The junctions contain the ternary complex of spectrin, F-actin, and protein 4.1R, as well as the
actin-binding proteins tropomyosin, tropomodulin, adducin, and dematin. Protein 4.1R enters into an
additional ternary interaction with the transmembrane proteins GPC and p55 and can also bind to band
3, in the form of a dimer, which also carries GPA. The blood group proteins Rh, Kell, and XK also have
binding sites on protein 4.1R. Note, however, that the abundances of all transmembrane proteins except
GPA and GPC are low and therefore not all proteins will be present on all complexes.
4.1R: protein 4.1R; GLUT1: glucose transporter 1; GPA: glycophorin A; CA II: carbonic anhydrase II; GPC:
glycophorin C; PFK: phosphofructokinase; Hb: hemoglobin; GAPDH: glyceraldehyde 3-phosphate
dehydrogenase.
Modified with permission from: Salomao, M, Zhang, X, Yang, Y, et al. Protein 4.1R-dependent multiprotein complex; new insights
into the structural organization of the red blood cell membrane. Proc Natl Acad Sci USA 2008; 105:8026. Copyright © 2008
National Academy of Sciences, USA.
Southeast Asian ovalocytosis
The peripheral blood smear shows ovalocytes, several of which exhibit longitudinal slits or a dense
central band (ie, stomatocytic elliptocytes). The two arrows point to longitudinal slits; the arrowhead
points to dense central band.
Courtesy of William C Mentzer, MD.
Spherocytes
Peripheral blood smear shows multiple spherocytes, which are small, dark, dense hyperchromic red cells
without central pallor (arrows). These findings are compatible with hereditary spherocytosis or
autoimmune hemolytic anemia.
Courtesy of Carola von Kapff, SH (ASCP).
Major causes of splenomegaly
Congestive
Cirrhosis
Heart failure
Thrombosis of portal, hepatic, or splenic veins
Malignancy
Lymphoma, usually indolent variants
Acute and chronic leukemias
Polycythemia vera
Multiple myeloma and its variants
Essential thrombocythemia
Primary myelofibrosis
Primary splenic tumors
Metastatic solid tumors
Infection
Viral – Hepatitis, infectious mononucleosis, cytomegalovirus
Bacterial – Salmonella, Brucella, tuberculosis
Parasitic – Malaria, schistosomiasis, toxoplasmosis, leishmaniasis
Infective endocarditis
Fungal
Inflammation
Sarcoid
Serum sickness
Systemic lupus erythematosus
Rheumatoid arthritis (Felty syndrome)
Infiltrative, nonmalignant
Gaucher disease
Niemann-Pick disease
Amyloid
Other lysosomal storage diseases (eg, mucopolysaccharidoses)
Langerhans cell histiocytosis
Hemophagocytic lymphohistiocytosis
Rosai-Dorfman disease
Hematologic (hypersplenic) states

Acute and chronic hemolytic anemias, all etiologies
Sickle cell disease (children)
Following use of recombinant human granulocyte colony-stimulating factor
Red blood cell abnormalities in hereditary spherocytosis: role of the spleen
RBC property Controls HS HS-Splenect
Number of subjects 37 25 23
Hemoglobin (g/dL) 13.9±1.0* 12.2±1.5 15.2±1.3
Reticulocytes (percent) 1.0±0.3 6.7±3.5 2.1±1.0
MCHC reticulocytes (g/dL) 26.6±1.3 30.2±2.5 31.2±1.2
MCHC mature RBC (g/dL) 32.2±0.7 36.1±1.6 36.1±0.8
RBC: red blood cells; HS: hereditary spherocytosis; HS-Splenect: splenectomized patients with HS; MCHC:
mean corpuscular hemoglobin concentration.
* Values are mean ±1 standard deviation.
Note that splenectomy corrected the anemia and reduced the reticulocyte percentage almost to normal
in patients with HS, but did not alter the spherocytic changes, as reflected by the increased values for
MCHC, either in the reticulocytes or the mature red cells.
Data from: Da Costa L, Mohandas N, Sorette M, et al. Temporal differences in membrane loss lead to distinct reticulocyte features
in hereditary spherocytosis and in immune hemolytic anemia. Blood 2001; 98:2894.
Distinguishing features between hereditary spherocytosis (HS), hereditary

elliptocytosis (HE), and Southeast Asian ovalocytosis on the blood smear,
ektacytometry, and EMA binding
RBCs from patients with HS, HE, and SAO have different properties that can be distinguished using
specialized laboratory tests. Ektacytometry (Osmoscan) measures the deformability of the RBCs (on the
Y-axis) across a gradient of osmolalities (on the X-axis). The minimal deformability index on the left of the
scan is the osmolality where hemolysis occurs. EMA binding measures the band 3 content of RBCs, with
the control in white and the patient samples in red (pink is the region of overlap).
(A) HS:
The blood smear shows spherocytes.
On ektacytometry, all measures of deformability (all parts of the tracing) are below the values for
normal RBCs, consistent with a decrease in RBC minimal and maximal deformability. The minimal
deformity is shifted to the right.
For EMA binding, the curve is shifted to the left due to reduced band 3 content.
(B) HE:
The blood smear shows elliptocytes.
On ektacytometry, the peak deformability (peak of the graph) is lower, consistent with lower
maximal flexibility and decreased deformability under shear stress, but the outer edges of the peak
(including Omin, the osmolality at which 50% of RBCs lyse) are relatively normal, consistent with less
severe (or no) hemolysis in most cases.
For EMA binding, band 3 content is slightly increased in full elliptocytes and much lower in
elliptocyte fragments from a severe HE patient.
(C) SAO:
The blood smear shows oval-shaped RBCs with 1 or 2 slits (also called theta cells or knizocytes)
On ektacytometry there is no discernable deformability across a wide osmotic gradient
(characteristically nearly flat curve).
For EMA binding, the 8 amino acid deletion renders lysine 430 inaccessible to EMA, although total
band 3 content is normal.
EMA: eosin-5-maleimide; HE: hereditary elliptocytosis; HS: hereditary spherocytosis; RBCs: red blood cells;
SAO: Southeast Asian ovalocytosis.
Reproduced from: Zaidi AU, Buck S, Gadgeel M, et al. Clinical Diagnosis of Red Cell Membrane Disorders: Comparison of Osmotic
Gradient Ektacytometry and Eosin Maleimide (EMA) Fluorescence Test for Red Cell Band 3 (AE1, SLC4A1) Content for Clinical
Diagnosis. Front Physiol 2020; 11:636. Available at: https://www.frontiersin.org/articles/10.3389/fphys.2020.00636/full. Copyright
© 2020 The Authors. Reproduced under the terms of the Creative Commons Attribution License 4.0.
The osmotic fragility test in hereditary spherocytosis
This figure shows results of an incubated osmotic fragility test performed on red cells from an adult
patient with hereditary spherocytosis, showing markedly increased osmotic fragility. Note that the
patient's red cells were >60 percent hemolyzed at a saline concentration (0.7 g/dL) that did not cause any
osmotic lysis in normal, incubated red cells.
Provided by Dr. Rebecca Connor.
Hereditary pyropoikilocytosis
The peripheral blood smear shows elliptocytes, poikilocytes, microcytes, and red cell fragments. The
patient was a compound heterozygote for two different variants affecting alpha-spectrin.
Hereditary pyropoikilocytosis
The peripheral blood smear shows an abundance of spherocytes as well as elliptocytes and microcytes.
Normal peripheral blood smear
High-power view of a normal peripheral blood smear. Several platelets (arrowheads) and a normal
lymphocyte (arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter
of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor
(dashed arrow) should equal one-third of its diameter.
Courtesy of Carola von Kapff, SH (ASCP).
Conceptual framework for inherited hemolytic anemias
Hemoglobinopathies and membrane disorders tend to have characteristic abnormalities of RBC

morphology on the peripheral blood smear. Membrane disorders may have nonspecific findings or bite
cells on the blood smear. Refer to UpToDate for other distinguishing features among these conditions
and the approach to diagnostic testing.
RBC: red blood cell; LDH: lactate dehydrogenase; Hb: hemoglobin; G6PD: glucose-6-phosphate
dehydrogenase; PK: pyruvate kinase; SAO: Southeast Asian ovalocytosis; HPP: hereditary
pyropoikilocytosis.
* Hemoglobinopathies can often coexist (eg, sickle-beta thalassemia; Hb E-beta thalassemia; Hb SC

disease). Not all forms of thalassemia cause hemolysis; hemolysis is seen with hemoglobin H disease and
transfusion-dependent beta thalassemia, but not with milder forms of thalassemia such as one or two
alpha globin gene deletions or heterozygous beta thalassemia.
Vaccinations for children with impaired splenic function and children

undergoing splenectomy in the United States*
2 to 10 years Revaccination
Vaccine <2 years old >10 years old
old (booster doses
Pneumococcus 4-dose series of 1 dose of PPSV23 ≥8 weeks after last Revaccinate with
PCV13 PCV13 at 2, 4, 6, dose of PCV13 (if 4-dose PCV13 series PPSV23 every 5
(Prevnar) and and 12 to 15 previously given) ¶ years Δ ◊
PPSV23 months of age
(Pneumovax)
Haemophilus ActHIB, Hiberix, Recommended only if not previously Not required

influenzae type b Pentacel: 4-dose vaccinated, vaccination status is
Hib (ActHIB, series at 2, 4, 6, unknown, or primary series is
Hiberix, and 12 to 15 incomplete ¥ǂ
Pentacel § , or months of age
PedvaxHIB) OR
PedvaxHIB: 3-dose
series at 2, 4, and
12 to 15 months of
age
Meningococcus 4-dose series of Menveo, Menactra, or MenQuadfi ¶¶ : 2 Revaccinate at

serotype ACWY Menveo at 2, 4, 6, doses ≥8 weeks apart ΔΔ intervals based on
MenACWY and 12 months of age:
(Menactra, age † **
Age <7 years: 3
Menveo, or years after
MenQuadfi) completion of
primary series
and every 5
years thereafte
Age ≥7 years:
every 5 years
Meningococcus Not recommended until age 10 Trumenba: 3 doses 1 year after

serotype B at 0, 1 or 2, and 6 completing the
MenB-FHbp months primary series and
(Trumenba) every 2 to 3 years
OR
or MenB-4C thereafter
Bexsero: 2 doses
(Bexsero)
given ≥1 month
apart
Seasonal 1 dose annually for children >6 months §§ Annually at start o

influenza ◊◊ influenza season
This table should be used in conjunction with the UpToDate topic on prevention of infection in patients
with impaired splenic function and the individual topics on pneumococcal, meningococcal, and influenza
vaccination. In addition to the vaccines above, patients with impaired splenic function should also receive
all routinely recommended age-appropriate vaccines. For patients undergoing elective splenectomy,
vaccinations should be given at least 14 days prior to the procedure and ideally 10 to 12 weeks prior. For
patients undergoing emergency splenectomy, vaccine series should be started 14 days after
splenectomy. For patients with nonsurgical asplenia or hyposplenism, vaccinations should be given as
soon as impaired splenic function is recognized.
* Available vaccine formulations and recommendations may differ outside of the United States.
¶ For children aged 2 to 6, give two doses of PCV13 if the four-dose PCV series is incomplete and <3
doses have been given; if incomplete and three doses have been given, give a single dose. For children
>6 years old, give a single dose of PCV13. Following receipt of the appropriate number of PCV13 doses,
give PPSV23. All pneumococcal vaccine doses should be given ≥8 weeks apart.
Δ Some experts prefer to given the second dose of PPSV23 three years after the first dose of PPSV23 in
patients with sickle cell disease.
◊ This recommendation differs from the Advisory Committee on Immunization Practices, which
recommends a single revaccination dose of PPSV23 five years after the first PPSV23 dose.
§ Pentacel is a combination vaccine that targets diphtheria, pertussis, polio, and tetanus in addition to H.
influenzae type B.
¥ For children <5 years old with anatomic or functional asplenia who are unvaccinated or who received
only one dose before 12 months of age, give two doses eight weeks apart; if two or more doses were
given before 12 months of age, then give one dose at least eight weeks after the last dose. For
unvaccinated patients ≥5 years old, give one dose.
‡ For unvaccinated children ≥15 months undergoing an elective splenectomy, give one dose at least 14
days prior to the procedure.
† Only Menveo can be given before age 2. Menactra is not recommended for use in children <2 years old
with impaired splenic function.
** If the first dose is given at ≥7 months of age, give two doses. The second dose should be given ≥12
weeks after the first AND when the child is >1 year old.
¶¶ Menactra must be administered at least four weeks after the last dose of PCV13.
ΔΔ Menactra, Mevneo, or MenQuadfi can be given at age 2 or greater. Each should be given as a two-
dose series spaced at least 8 weeks apart.
◊◊ Although live attenuated vaccines can be safely given to patients with impaired splenic function who
lack other immunosuppressive conditions, the inactivated influenza vaccine is preferred over the live
formulation because it is equally effective.
§§ Children <9 years old who did not receive a total of two doses of influenza vaccine previously should
receive two doses given ≥4 weeks apart followed by annual revaccination with a single dose thereafter.
Adapted from: Robinson CL, Bernstein H, Poehling K, et al. Advisory Committee on Immunization Practices Recommended
Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2020. MMWR Morb Mortal Wkly
Rep 2020; 69:130.
Vaccinations for adults (age >19 years) with impaired splenic function and
adults undergoing splenectomy in the United States*
Vaccine Primary series Revaccination (booster)
Pneumococcal vaccine 1 dose of PCV20 or PCV15. If Not applicable

PCV20 alone or PCV15 plus PCV15 is used, 1 dose of PPSV23
PPSV23 ≥8 weeks later
Haemophilus influenzae type b 1 dose ¶ Not applicable

vaccine
Hib
Meningococcal serotype ACWY 2 doses at least 8 weeks apart Δ Every 5 years

vaccine
MenACWY (Menactra,
Menveo, or MenQuadfi)
Meningococcal serotype B 2 doses of MenB-4C at least 1 1 year after completing the

MenB-FHbp (Trumenba) or month apart or 3 doses of MenB- primary series and every 2 to 3
MenB-4C (Bexsero) FHbp at 0, 1 to 2, and 6 months ◊ years thereafter
Seasonal influenza virus 1 dose annually at the start of Repeat annually at start of
influenza season influenza season
This table should be used in conjunction with the UpToDate topic on prevention of sepsis in patients with
impaired splenic function. In addition to the vaccines above, patients with impaired splenic function
should also receive all routinely recommended age-appropriate vaccines (including coronavirus disease
2019 [COVID-19] vaccination). For patients undergoing elective splenectomy, vaccinations should be
given at least 14 days prior to the procedure and ideally 10 to 12 weeks prior. For patients undergoing
emergency splenectomy, vaccine series should be started 14 days after splenectomy. For patients with
nonsurgical asplenia or hyposplenism, vaccinations should be given as soon as impaired splenic function
is recognized.
PCV20: 20-valent pneumococcal conjugate vaccine; PCV15: 15-valent pneumococcal conjugate vaccine;
23-valent pneumococcal polysaccharides: PPSV23.
* Available vaccine formulations and recommendations may differ outside of the United States.
¶ Hib vaccination is recommended for all adults who have not been previously vaccinated or if
vaccination status is unknown.
Δ If primary series already received, continue revaccinating every 5 years.
◊ If not already received.
Contributor Disclosures
Theodosia Kalfa, MD, PhD No relevant financial relationship(s) with ineligible companies to
disclose. Robert T Means, Jr, MD, MACP Consultant/Advisory Boards: Affinergy [Iron-related diagnostic
tests]; Pharmacosmos Therapeutics Inc. [Iron deficiency in pregnancy]. All of the relevant financial
relationships listed have been mitigated. Jennifer S Tirnauer, MD No relevant financial relationship(s)
with ineligible companies to disclose.
Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are
addressed by vetting through a multi-level review process, and through requirements for references to be
provided to support the content. Appropriately referenced content is required of all authors and must
conform to UpToDate standards of evidence.
Conflict of interest policy

Hereditary Spherocytosis - UpToDate

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Hereditary Spherocytosis - UpToDate

Uploaded by

Copyright:

Available Formats

12/26/23, 11:14 PM Hereditary spherocytosis - UpToDate

Official reprint from UpToDate®

Literature review current through: Nov 2023.

● HE and HPP – (See "Hereditary elliptocytosis and related disorders".)

Overview of the proteins and genes involved — HS is caused by quantitative deficiency of

● Spectrin – Erythrocyte spectrin is composed of alpha-beta heterodimers; the proteins are

● Methods of analysis – Quantitative evaluation of the RBC membrane proteins with

The introduction of next generation DNA sequencing to clinical diagnostics in

• Ankyrin deficiency due to ANK1 variants is accompanied by secondary spectrin

• SLC4A1 variants can also cause secondary band 4.2 deficiency.

● HS may be inherited in an autosomal dominant fashion, caused by heterozygous

● An additional 5 to 15 percent of cases are autosomal recessive, caused by biallelic variants

● The remaining 15 to 20 percent of cases appear to be due to de novo pathogenic variants

● ANK1-associated HS is typically an autosomal dominant disease, caused by a monoallelic

HS due to SLC4A1 pathogenic variants is typically an autosomal dominant disease presenting as

● Cryohydrocytosis – Certain heterozygous SLC4A1 single amino-acid substitutions in the

● Stomatocytosis and dyserythropoiesis – A de novo band 3 variant (p.G796R-band3

SLC4A1 pathogenic variants appear to cause approximately 5 percent of HS cases. (See

However, this may be an underestimate since SLC4A1-associated HS is typically mild and

Beta spectrin or alpha-spectrin deficiency due to SPTB or SPTA1 pathogenic

HS due to alpha-spectrin deficiency is an autosomal recessive disease. Each SPTA1 allele

In addition to phagocytosis, the spleen also exposes RBCs to an acidotic, oxidizing,

Disease prevalence — HS is seen in all populations but appears to be especially common in

Frequency of different genetic variants — Cohort studies providing relative frequencies of

Compound heterozygous variants in SPTA1 causing autosomal recessive disease were

● In a study of 95 patients in the Netherlands evaluated by next-generation sequencing

• SPTA1 – 36 percent, possibly representing a bias of ordering genetic testing in patients

Exacerbations of anemia may also occur in certain settings:

Iron deficiency is rare in hereditary spherocytosis, as in all hereditary hemolytic anemias;

Complications of hemolysis — Common complications of hemolysis in individuals with HS

Hyperbilirubinemia may be exacerbated by concomitant Gilbert syndrome. (See "Unconjugated

There is no evidence of an increased risk of splenic rupture.

syndrome (inherited disorder of bilirubin glucuronidation) [117]. (See "Gilbert syndrome",

Obstructive jaundice or cholecystitis is treated similarly to that in individuals without HS. If

EVALUATION Thiếu máu tán huyết Coomb âm, và HC hình cầu/PMNB

When to suspect HS — The diagnosis of HS should be suspected in an individual with direct

HS is a non-immune form of hemolysis; the DAT is negative. (See "Overview of hemolytic

However, the following are appropriate in virtually all individuals:

● If an infant with hyperbilirubinemia or other findings of non-immune hemolytic anemia

● Spherocytes ( picture 2) on the peripheral blood smear. The percentage of spherocytes

• Anisocytic spherocytes – Ankyrin deficiency

diagnose HS versus normal RBCs appear to be in the ranges of 93 to 96 and 93 to 99

● Osmotic gradient ektacytometry – Osmotic gradient ektacytometry (OGE) is the

of microspherocytes and CDA-II may produce an ektacytometry curve resembling HS

● Cryohemolysis – In the cryohemolysis test, RBCs are suspended in a hypertonic solution,

between xerocytosis and spherocytosis, before proceeding to splenectomy, OGE as well as

More importantly, misdiagnosis of hereditary xerocytosis (HX) as spherocytosis has to be

● Cincinnati Children's Molecular Genetics Laboratory:

● Blood Disease Reference Laboratory Program at Yale University:

● Mayo Medical Laboratories:

Differential diagnosis — The differential diagnosis of HS includes a number of other hemolytic

It is especially important to distinguish between HS and HSt because HS is generally

● Neonatal alloimmune hemolytic anemia – Neonatal alloimmune hemolytic anemia,

● Infantile pyknocytosis – Infantile pyknocytosis is a disorder of unknown etiology in which

● Congenital dyserythropoietic anemia (CDA) – CDA type II is an autosomal recessive rare

member of the cytoplasmic coat protein II (COPII) complex, which is implicated in

● Autoimmune hemolytic anemia (AIHA) – AIHA is caused by increased RBC destruction

Monitoring — The frequency of patient monitoring depends on disease severity and

normal neonatal hyposplenism resolves, and hemoglobin frequently decreases enough to

● Treatment of hyperbilirubinemia – If a neonate is suspected of having HS (eg, based on

● Considerations related to splenomegaly – There are no special restrictions (eg, no

Transfusions — Blood transfusion is often required in infancy, even in mild autosomal